

ROBERT M. SWIFT, MD, PHD

Curriculum Vitae Index

Education	1
Postgraduate Training.....	1
Postgraduate Honors and Awards	1
Professional License	1
Academic Appointments	2
Hospital Appointments	2
Other Appointments	2
Hospital Committees.....	4
University Committees	4
Membership in Societies	4
Original Publications in Peer-Reviewed Journals	5
Books and Book Chapters	11
Non Peer-Reviewed Publications.....	13
Corporate Authorship or Multicenter Trials	13
Publications Submitted or in Preparation	13
Abstracts	13
Invited Presentations—Regional and National.....	20
Invited Presentations—International	27
Grants and Contracts (Active).....	29
Grants and Contracts (Pending)	30
Grants and Contracts (Completed).....	30
University Teaching Roles	34
Hospital Teaching Roles	34
Mentoring.....	34

Curriculum Vitae

ROBERT M. SWIFT, M.D., PH.D.

Address:	Brown University Ctr. for Alcohol & Addiction Studies Box G-S121-4 Providence, RI 02912	VA Medical Center Research Building 35 830 Chalkstone Ave. Providence, RI 02908
Phone:	401.863.6634	401.457.3066
Fax:	401.863.6647	401.457.3305
E-mail:	Robert_Swift@brown.edu	

EDUCATION

1972 A.B. University of Chicago, Chicago, Illinois (Biology)

1977 Ph.D. University of Chicago, Department of Pharmacological and Physiological Sciences.
Dissertation: "Studies on the Organization and Function of the GABA System in the Striatum and Substantia Nigra of the Rat Brain."

1979 M.D. University of Chicago, Pritzker School of Medicine (With Honors)

POSTGRADUATE TRAINING

1979-1980 Internship, Hospital of St. Raphael, New Haven, Connecticut, Flexible Internship

1980-1983 Residency, Yale University Department of Psychiatry

1982-1983 Chief Residency, Yale-New Haven Hospital, Consultation-Liaison Services, Neuropsychiatric Evaluation Unit Yale-New Haven Hospital

POSTGRADUATE HONORS AND AWARDS

1972-1976 Recipient of NIMH Neurosciences Training Grant

1976 Sigma Xi

1977 Harry Ginsberg Award of the University of Chicago in Physiology

1979 General Honors with M.D. Degree

1984 American College of Neuropsychopharmacology Travel Fellowship Award

1993 Honorary Degree, Master of Arts Ad Eudem, Brown University

1994-1998 Chosen one of the top psychiatrists in Rhode Island by *Rhode Island Monthly*

1997 Fellow, American Psychiatric Association, Distinguished Fellow, 2003

2000 Elected to membership, American College of Neuropsychopharmacology (ACNP)

2005 – 2011 Best Doctors in America

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

- Rhode Island Medical License: No. MD6225
- DEA License: No. AS2151809
- Board Certified in Adult Psychiatry by American Board of Psychiatry & Neurology, Oct. 1984
- Certificate of Added Qualifications in Addiction Psychiatry, October 1994, Recertified October 2004

ACADEMIC APPOINTMENTS

2001- Professor, Psychiatry & Human Behavior, Brown Medical School, Providence, RI
1997- Associate Director, Center for Alcohol & Addiction Studies, Brown Medical School
1992-2001 Associate Professor, Psychiatry & Human Behavior, Brown Medical School, Providence, RI
1983-1992 Assistant Professor, Psychiatry & Human Behavior, Brown Medical School, Providence, RI

HOSPITAL APPOINTMENTS

1997- Associate Chief of Staff for Research and Development, Providence VA Medical Center, Providence, RI
1990-1997 Psychiatrist-In-Chief, Roger Williams Medical Center, Providence, RI
1990-1995 Medical Director, Substance Abuse Treatment Program, Providence VA Medical Center, Providence, RI
1989- Courtesy Staff, Miriam Hospital, Providence, RI
1988-1990 Medical Director, Methadone Clinic, Providence VA Medical Center, Providence, RI
1985-1988 Consultant Psychiatrist, New Bedford Area Center for Human Services, Alcohol and Drug Programs, New Bedford, MA
1985-1987 Consultant Psychiatrist, Providence Veterans Administration Medical Center, Providence, RI
1984-1990 Director of Division of Psychiatry, Roger Williams General Hospital, Providence, RI
1983- Consultant Psychiatrist, Women and Infants Hospital, Providence, RI
1983- Staff Psychiatrist, Rhode Island Hospital, Providence, RI
1983-1984 Staff Psychiatrist, Roger Williams General Hospital, Providence, RI
1981-1983 Consultant, Clonidine Detoxification Study, Substance Abuse Treatment Unit, Connecticut Mental Health Center
1981-1983 Medical Staff, Hall-Brooke Hospital, Westport, Connecticut

OTHER APPOINTMENTS (1995 and later)

2011-2013 Elected Member, VA Office of Research and Development, Field Research Advisory Group (FRAC)
2010-2013 Regular Member, The Neural Basis of Neuropathology, Addiction and Sleep (NPAS) Study Section, Center for Scientific Review, NIH
2010- Member, Scientific Advisory Board, VA VISN 17 Center of Excellence on PTSD
2010 Member, CSAT-KAP Treatment Improvement Protocols User Liaison Group
2009 Member, Program Committee, Research Society on Alcoholism
2008 Chair, Special Review Committee at NIAAA to Review proposals for long-term follow up of the Combine Study
2007-2011 Member NIH Director's Innovator Award Grant Review Committee
2007 Chair, NIDA Clinical Trials Network (CTN) Grant Review Committee
2006 Member CSAT/SAMSHA Consensus Panel on "Maintenance Medications for Alcoholism Treatment".
2005-2010 Ad hoc Member, NPAS Grant Review Committee, NIH
2005-2007 Elected Secretary, Research Society on Alcoholism

2003-2005 Elected to Board of Directors, Research Society on Alcoholism

2003 Chair, SBIR/STTR Special Review Committee, NIAAA

2003- Chair, Pharmacology Subcommittee, COMBINE Study Research Group

2002- Reviewer for *Journal of the American Medical Association (JAMA)*

2002 Reviewer for *The Lancet*

2002- Faculty Mentor to Travel Awardees, ACNP Annual Meeting

2001-present Chair, Data Safety and Monitoring Board, NIAAA Center for Translational Neuroscience (CTNA) at Yale University

2001-2002 Appointed as Visiting Researcher for NIAAA/NIH/CSAT Researcher in Residence Program, North Carolina

2001- Member, Program Committee, American College of Neuropsychopharmacology (ACNP) Annual Meeting

2000-2001 Member, Program Committee, Research Society for Alcoholism (RSA) Annual Meeting

2000-2001 Chair, Treatment Committee and Member of Operations Committee, Project COMBINE

1999-2000 Chair, NIAAA Alcoholism Treatment Grant Review Committee (AA3)

1999- Member, Election Committee, Research Society for Alcoholism

1998 National Institute on Drug Abuse Taskforce on Craving

1998- President, Ocean State Research Institute

1997- Member, Education Committee, Research Society for Alcoholism

1997-2003 Board of Directors, Marathon/Phoenix House Drug Treatment Programs of New England, Inc.

1997 Group Facilitator, CSAT Treatment Improvement Protocol (TIP) on Naltrexone for the Treatment of Alcoholism.

1997 Member, NIAAA Alcohol Center Grant Review Committee (SEP)

1997 Member, National Institute of Drug Abuse Center Grant Review Committee

1997- Reviewer for *New England Journal of Medicine*

1997- Reviewer for *Alcohol*

1997 Reviewer for *J. Substance Abuse Treatment*

1997 Reviewer for *Substance Abuse*

1996- Member, NIAAA Alcoholism Treatment Grant Review Committee (ALCP-1/AA3)

1996- Committee on National Advocacy—Research Society for Alcoholism (RSA)

1996- Member, Scientific Advisory Committee of the NIAAA-funded Alcohol Center at the Medical University of South Carolina

1996 Ad Hoc Member, VA Cooperative Studies Center Grant Review Committee

1995-1996 Member of the Academic Consortium of the American Psychiatric Association

1995-1996 Chair, NIAAA Grant Special Review Committees

1995 Reviewer for *Psychopharmacology*

1994-1998 Ad Hoc Member, VA Merit Review Grant Committee

1994-1996 Ad Hoc Member, NIAAA Grant Review Committee (ALCP1)

1994-1995 Consultant to Government of Switzerland on Opiate Dependence Treatment Programs

HOSPITAL COMMITTEES

2009-	Member, VA VISN 1 Research Committee
2003	Chair, Administrative Investigative Board, Syracuse VA Medical Center
1999-2004	Chair, Residency Supervision Committee
1997-	Member, Clinical Executive Board, Providence VA Medical Center
1997-1998	Ex Officio Member, Institutional Review Board, Providence VA Medical Center
1998-1999	Research and Development Committee, Providence VA Medical Center
1997-	Member, Research Safety Committee, Providence VA Medical Center
1997-	Member, Animal Research Committee (IACUC), VA Medical Center
1994-1998	Executive Committee of the Medical Staff, Roger Williams Medical Center
1984-1988	Pharmacy and Therapeutics Committee, Roger Williams General Hospital

UNIVERSITY COMMITTEES

2009-2010	Member, Search Committee for Chair of the Department of Medicine
2009	Member, Dean's Ad Hoc Committee on Research Grant Mismanagement
2003-2006	Member, Brown University Committee on Medical Faculty Appointments (CMFA)
2001	Member, Brown University Selection Committee for Vice-President of Research
1997-2000	Elected Member, Medical Faculty Executive Committee (MFEC), Brown Medical School
1997-	Senior Management Committee, Brown University Ctr. for Alcohol and Addiction Studies
1995-	Training Committee, Brown University Center for Alcohol and Addiction Studies
1987-	Member, Policy and Management Advisory Committee (PMAC), Department of Psychiatry and Human Behavior, Brown Medical School
1987-1989	Associate Director (for Mental Health), Brown University AIDS Task Force
1987-1989	Member, Impaired Physicians Committee, Rhode Island Medical Society
1985-1990	Peer Review Committee, Dept. of Psychiatry and Human Behavior, Brown Medical School
1985-1990	Residency Policy Committee, Department of Psychiatry and Human Behavior, Brown Medical School
1984-1987	Residency Selection Committee, Department of Psychiatry and Human Behavior, Brown Medical School

MEMBERSHIP IN PROFESSIONAL SOCIETIES

- American College of Neuropsychopharmacology (ACNP)
- American Psychiatric Association (APA)—Distinguished Fellow
- Asian Pacific Society for Alcohol and Addiction Research (APSAAR)
- International Society for Biomedical Research on Alcoholism (ISBRA)
- Research Society for Alcoholism (RSA)
- Rhode Island Psychiatric Society
- Rhode Island Society for Addiction Medicine (RISAM) – Board of Directors

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Swift RM, Hoffman PC & Heller A. (1978). Activity dependent changes in substantia nigra GABA. *Brain Research*, 156:1811-86.
2. Deyo SN, Swift RM & Miller RJ. (1979). Morphine and endorphins modulate dopamine turnover in rat median eminence. *Proc Natl Acad Sci*, 76, 3006-09.
3. Bernstein JE & Swift RM. (1979). Relief of intractable pruritus with naloxone. *Arch Dermatology*, 115, 1366-67.
4. Deyo SN, Swift RM, Miller RJ & Fang V. (1980). Development of tolerance to the prolactin releasing action of morphine and its modulation by hypothalamic dopamine. *Endocrinology*, 106, 1469-74.
5. Bernstein JE, Swift R, Soltani K & Lorincz AL. (1981). Inhibition of axon reflex vasodilatation by topically applied capsaicin. *J Invest Dermatol*, 76, 394-95.
6. Bernstein JE, Swift RM, Soltani K & Lorincz AL. (1982). Antipruritic effect of an opiate antagonist, naloxone hydrochloride. *J Invest Dermatol*, 78, 82-83.
7. Swift RM & Black H. (1984). Essential hypertension. Psychiatric aspects and use of psychotropics. *Psychosomatics*, 25(10), 737-743.
8. Gaspari J, Swift RM, Kleber H, et al. (1985). Prevalence of movement disorder in a methadone maintained population. *J Nerv Mental Dis*, 173(6), 373-376.
9. Slaby AE & Swift RM (1985). Diagnosing and managing drug-induced psychiatric emergencies. *Psychiatric Med* 3(3), 233-252.
10. Swift RM (1986). Negotiating psychiatric hospitalizations within restrictive admissions criteria. *Hosp Comm Psychiatry*, 37(6), 619-623.
11. Swift RM & Thayer W. (1987). Increased obstipation in a patient with scleroderma due to lithium. *J Clinical Psychopharmacol*, 7(5), 358-359.
12. Friedman JH, Max J & Swift R. (1987). Idiopathic Parkinson's disease in a chronic schizophrenic: long-term treatment with clozapine and L-DOPA. *Clin Neuropharm*, 10(5), 470-475.
13. Swift RM (1989). Diurnal variation in methylphenidate response in major depression. *J Clinical Psychopharmacol*, 9(6), 452.
14. Swift RM, Griffiths W, Camara P & Dextraze P. (1989). False positive drug screens from quinine in tonic water. *Addictive Behaviors*, 14(2), 213-215.
15. Swift RM, Dudley M, DePetrillo P, Camara P & Griffiths W. (1989). Altered methadone pharmacokinetics in pregnancy: implications for dosage. *J Subst Abuse Treat*, 1, 453-460.
16. Swift RM & DePetrillo PB. (1990). Cocaine abuse and dependence. *RI Med J*, 73(6), 265-270.
17. DePetrillo P, Swift R, Sanders M& Abernethy DR. (1990). A reverse-phase HPLC method for the determination of human platelet cyclic AMP. *J Chromatography*, 527, 421-427.
18. Swift RM & DePetrillo P. (1990). Human leukocyte beta-adrenergic stimulated cyclic AMP in ethanol intoxication and withdrawal. *Alcohol Clin Exp Res*, 14(1), 58-62.
19. Sullivan JT, Swift RM, Lewis DC. (1991). Benzodiazepine requirements during the alcohol withdrawal syndrome: Clinical implications of using a standardized withdrawal scale. *J Clin Psychopharmacology*, 11(5), 291-295.
20. DePetrillo PB, Swift RM (1992). Inhibitory effects of ethanol on human platelet cyclic AMP: Evidence for a protein kinase C mediated process. *Alcohol Clin Exp Res*, 16(3), 290-294.
21. Swift RM, Stout RL. (1992). Relationship between craving and anxiety in opioid withdrawal. *J Subst Abuse Treat*, 4, 19-26.
22. Mueller TI, Swift RM (1992). The AIDS Questionnaire: A rapid screening device for risk of exposure to HIV. *Am J Addictions*, 1(3), 203-209.

23. Mueller TI, Swift RM(1992). Co-morbidity of panic disorder and substance use disorders, *RI Medicine*, 75(5), 277-280.
24. Martin CS, Earleywine M, Musty RE, Perrine MW, Swift RM (1993). Development and validation of the biphasic alcohol effects scale. *Alcohol Clin Exp Res*, 17(1), 140-146.
25. Swift RM, Martin C, Swette L, LaConti A, Kackley N. (1992). Studies on a wearable, electronic, transdermal alcohol sensor. *Alcohol Clin Exp Res*, 16(4), 721-725.
26. Swift RM (1993). Transdermal ethanol. *Addiction*, 88, 1037-39.
27. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H. (1994). Naltrexone-induced alterations in human ethanol intoxication. *Am J Psychiatry*, 151, 1463-1467.
28. Swift RM (1995). Effect of naltrexone on human alcohol consumption. *J Clin Psychiatry*, 56(Suppl. 7), 24-29.
29. Swift RM, Davidson D, Kuznetsov O. (1996). Ondansetron alters human alcohol intoxication. *Biol Psychiatry*, 40(6), 514-519.
30. Davidson D, Swift R, Fitz E. (1996). Naltrexone increases the latency to drink alcohol in social drinkers. *Alcohol Clin Exp Res*, 20(4), 732-739.
31. Swift RM (1996). Matching observations to addiction theory. *Behavioral and Brain Sciences*, 19(4), 596-7.
32. Nirenberg TD, Cellucci T, Liepman MR, Swift RM, Sirota AD. (1996). Cannabis versus other illicit drug use among methadone maintenance patients. *Addictive Behaviors*, 10(4), 222-277.
33. Swift RM, Miller NS. (1997). Health care economics for addiction treatment clinicians. *J. Psychoactive Drugs*, 29(3), 255-262.
34. Swift RM (1997). The pharmacological treatment of alcohol dependence, *Med Health RI*, 80(3), 91-93.
35. Hutchison KE, Rohsenow D, Monti P, Palfai T, Swift R. (1997). Prepulse inhibition of the startle reflex: preliminary study of the effects of a low dose of alcohol in humans. *Alcohol Clin Exp Res*, 21(7), 1312-1319.
36. Davidson D, Camara P, Swift R. (1997). Pharmacokinetic and behavioral effects of low-dose intravenous alcohol in humans. *Alcohol Clin Exp Res*, 21(7), 1294-1299.
37. Swift R, Davidson D, Rosen S, Fitz E, Camara P. (1998). Naltrexone effects on diazepam intoxication and pharmacokinetics in humans. *Psychopharmacology* 135(3), 256-26.
38. Swift RM, Nirenberg T, Femino J. (1998). Alcoholic patients attitudes and experience toward pharmacotherapy for alcoholism. *J Addictive Diseases*, 17(3), 35-47.
39. Swift RM, Davidson D (1998). Hangover: Mechanisms and Mediators. *Alcohol and Research World*, 22(1), 54-6.
40. Hutchison KE, Monti PM, Rohsenow DJ, Swift RM, Colby SM, Gnys M, Niaura RS, Sirota AD. (1999). Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. *Psychopharmacology* 142(2), 139-143.
41. Davidson D, Bird C, Swift R. (1999). Effects of naltrexone on alcohol self-administration in heavy drinkers. *Alcohol Clin Exp Res*, 23(2), 195-203.
42. Monti P, Rohsenow DJ, Hutchison KE, Swift RM, Mueller T, Colby S, Brown SA, Gulliver SB, Gordon A, Abrams DB. (1999). Naltrexone's effect on cue-elicited craving among alcoholics in treatment. *Alcohol Clin Exp Res*, 23(8), 1386-1394.
43. Hutchison KE, Niaura R, Swift R. (1999). Smoking cues decrease prepulse inhibition of the startle response and increase subjective craving in humans. *Exp and Clin Psychopharmacology*, 99(7), 250-256.
44. Hutchison KE, Wood MD, Swift R. (1999). Personality factors moderate subjective and psychophysiological responses to d-amphetamine in humans. *Exp and Clin Psychopharmacology*, 7(4), 493- 501.

45. Palfai TP, Davidson D, Swift R. (1999). The influence of naltrexone on cue-elicited craving among hazardous drinkers: the moderational role of positive outcome expectancies. *Exp and Clin Psychopharmacology*, 7(3), 266-273.
46. Hutchison KE, Swift R. (1999). Effect of d-amphetamine on pre-pulse inhibition of the startle reflex in humans. *Psychopharmacology* 143(4), 394-400.
47. Swift RM (1999). Medications for alcohol craving. *Alcohol Health and Research*, 23(3), 207-213.
48. Swift RM (1999). Drug therapy of alcohol dependence. *New Eng J Med*, 340(19), 1483-1489.
49. Hutchison KE, Niaura R, Swift R. (2000). Smoking high nicotine cigarettes reduces pre-pulse inhibition of the startle reflex in humans. *Psychopharmacology* 150, 244-252.
50. Swift RM (2000). Transdermal alcohol measurement for estimation of blood alcohol concentration. *Alcohol Clin Exp Res*, 24(4), 422-423.
51. Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, Colby SM, Kaplan G. (2000). Naltrexone's effects on reactivity to alcohol cues among alcoholic men. *J Abnormal Psychology* 109(4), 738-742.
52. Rohsenow DJ, Monti P, Colby SM, Swift RM, Martin RA, Mueller TI, Gordon A, Eaton CA. (2000). Predictors of compliance with naltrexone among alcoholics. *Alcohol Clin Exp Res*, 24(10), 1542-1549.
53. Hutchison KE, Swift R, Rohsenow DJ, Monti PM, Davidson D, Almeida A. (2001). Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. *Psychopharmacology (Berl)*. 155(1), 27-34.
54. Flannery B, Roberts AJ, Cooney N, Swift RM, Anton R, Rohsenow DJ. (2001). The role of craving in alcohol use, dependence, and treatment. *Alcohol Clin Exp Res*, 25(2), 299-308.
55. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, Brown RA, Gordon A, Abrams DB, Niaura RS & Asher MK. (2001). Naltrexone and cue exposure with coping and communication skills training for alcoholics: Treatment process and 1-year outcomes. *Alcohol Clin Exp Res*, 25(11), 1634-47.
56. Anton, R.F., Dominick, C., Bigelow, M., Westby, C. and the CDTect Research Group Doot, M., Kranzler H., Miller, B., O'Brien, C., Pettinati, H., Ramirez, L., Swift, R., Zweben, A. (2001). Comparison of Bio-Rad %CDT TIA and CDTect as laboratory markers of heavy alcohol use and their relationships with g-glutamyltransferase. *Clinical Chemistry* 47:1769-1775.
57. Davidson D, Hutchison K, Dagon C & Swift R. (2002). Assessing the stimulant effects of alcohol in humans. *Pharmacol Biochem Behavior*, 72(1-2), 151-6.
58. Smoger SH, Looney SW, Blondell RD, Wieland LS, Sexton L., Rhodes SB & Swift RM(2002). Hospital use of ethanol survey. *J Addictive Diseases* 21(2), 65-74.
59. Hitsman B, Abrams DB, Shadel WG, Niaura R, Borrelli B, Emmons KM, Brown RA, Swift RM, Monti PM, Rohsenow DJ & Colby SM. (2002). Depressive symptoms and readiness to quit smoking in cigarette smokers in outpatient alcohol treatment. *Psych Addictive Behavior*, 16(3), 264-268.
60. Hutchison, KE, McGeary J, Smolen, A, Bryan AD, & Swift, RM (2002). The DRD4 VNTR polymorphism moderates craving after alcohol consumption. *Health Psychology* 21(2):139-46.
61. Anton, R.F., Lieber, C, Tabakoff, B. for the CDTect Study Group, Doot, M., Kranzler H., Lieber, C., Miller, B., O'Brien, C., Pettinati, H., Ramirez, L., Swift, R., Tabakoff, B., Zweben, A. (2002). Carbohydrate deficient transferrin and g-glutamyltransferase for the detection and monitoring of alcohol use: Results from a multisite study. *Alcoholism: Clinical and Experimental Research*, 26(8):1215-1222.
62. Blondell R, Looney S, Smoger R, Dodds H, Wieland S, Swift, R. (2003). Ethanol in formularies of U.S. teaching hospitals. *JAMA*, 289(5), 552.
63. Thomas C, Wallack S, Swift R, Bishop C, McCarty D, Simoni-Wastila L. (2003). Research to practice: Adoption of naltrexone in alcoholism treatment. *J Subst Abuse Treat*, 24(1), 1-11.
64. Swift RM (2003) Topiramate for the treatment of alcohol dependence: initiating abstinence. *Lancet* 361:1666-1667.

65. Zywiak WH, Stout RL, Trefry WB, LaGrutta JE, Lawson, CC, Khan, N., Swift RM, & Schneider RJ (2003) Alcohol relapses associated with September 11, 2001: A case report. *Substance Abuse* 24(2):123-128.
66. Anton RF & Swift RM (2003) Current pharmacotherapies of alcoholism: A U.S. perspective. *American Journal on Addictions* 12(suppl 1): 53-68.
67. Rohsenow DJ, Monti PM, Colby SM, Gulliver SB, Swift RM, Abrams DB. (2003) Naltrexone treatment for alcoholics: effect on cigarette smoking rates. *Nicotine Tobacco Research*, 5(2):231-236.
68. Hutchison KE, Wooden A, Swift RM, Smolen A., McGeary J., Bryan AD, & Adler L. (2003) Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. *Neuropsychopharmacology*, 28(10):1882-1888.
69. Pierucci-Lagha A, Modesto-Lowe V, Nellissery M, Kranzler HR, Swift R, Feinn R, Covault J. (2003) Effects of rapid tryptophan depletion on mood and urge to drink in patients with comorbid depression and alcohol dependence. *Psychopharmacology* 171(3):340-348.
70. Swift RM (2003) Direct measurement of alcohol and its metabolites. *Addiction* 98(suppl 2):73-80.
71. Hutchison KE, Rutter MC, Niaura R, Swift RM, Pickworth WB, Sobik L (2004) Olanzapine attenuates cue-elicited craving for tobacco. *Psychopharmacology (Berl)*. 175(4):407-13.
72. Kenna GA, McGeary JE, Swift RM (2004) Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 1. *Am J Health Syst Pharm*. 61(22):2372-2379.
73. Kenna GA, McGeary JE, Swift RM (2004) Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2. *Am J Health Syst Pharm*. 61(22):2380-2388.
74. Johnson BA, Swift RM, Ait-Daoud N, DiClemente CC, Javors MA, Malcolm RJ Jr. (2004) Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on antiepileptics. *Alcohol Clin Exp Res*. 28(2):295-301.
75. Johnson BA, Swift RM, Addolorato G, Ciraulo DA, Myrick H. (2005) Safety and efficacy of GABAergic medications for treating alcoholism. *Alcohol Clin Exp Res*. 29(2):248-54.
76. Swift R, Pettinati HM (2005). Choosing pharmacotherapies for the COMBINE Study--process and procedures: an investigational approach to combination pharmacotherapy for the treatment of alcohol dependence. *J Stud Alcohol (S15)*:141-7; discussion 140.
77. Weiss RD, Locastro JS, Swift R, Zweben A, Miller WR, Longabaugh R, Hosking JD (2005). Use of a "psychotherapy with no pills" treatment condition as part of a combined pharmacotherapy-psychotherapy research study of alcohol dependence. *J Stud Alcohol (S15)*:43-9; discussion 33.
78. Johnson BA, Mann K, Willenbring ML, Litten RZ, Swift RM, Lesch OM, Berglund M (2005). Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry. *Alcohol Clin Exp Res*, 29(8):1528-40.
79. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM (2005). Subjective and physiological responses to smoking cues in smokers with schizophrenia. *Nicotine Tobacco Res* 7(3):421-9.
80. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM (2005). Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. *Drug Alcohol Depend* 1;80(2):259-65.
81. Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, Davidson D, Swift R (2006). The Effect of Olanzapine on Craving and Alcohol Consumption. *Neuropsychopharmacology* 31(6):1310-7.
82. Anton RF, O'Malley SS, Ciraulo DA; Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BA, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A, for the COMBINE Study Research Group. (2006) Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study: A Randomized Controlled Trial. *JAMA* 295: 2003-2017.
83. McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R Jr. (2006) Genetic moderators of naltrexone's effects on alcohol cue reactivity. *Alcohol Clin Exp Res*. 30(8):1288-96.

84. Kranzler HR, Koob G, Gastfriend DR, Swift RM, Willenbring ML. (2006) Advances in the pharmacotherapy of alcoholism: challenging misconceptions. *Alcohol Clin Exp Res.* 30(2):272-81.
85. Swift R. (2006). Monograph Editor, Improving Outcomes in Alcohol Dependence Treatment. *J Clin Psychopharmacol.* 26(6suppl1):S1-S2.
86. Bohn MJ, Swift RM (2006) Prevalence and impact of alcohol dependence. *J Clinical Psychiatry* 677(suppl 14):6-13.
87. Kenna GA, Nielsen DM, Mello P, Schiesl A, Swift RM. (2007) Pharmacotherapy of dual substance abuse and dependence. *CNS Drugs.* 21(3):213-37.
88. Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, MacKinnon SV, Sirota AD, Kaplan GB. (2007) High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking. *Exp Clin Psychopharmacol.* 15(1):81-92.
89. Ray LA, Miranda R Jr, Kahler CW, Leventhal AM, Monti PM, Swift R, Hutchison KE. (2007) Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes among light smokers: a pilot study. *Psychopharmacology (Berl)*; 193(4):449-56.
90. Swift R. (2007). Emerging approaches to managing alcohol dependence. *Am J Health Syst Pharm.* 64(5 Suppl 3):S12-22.
91. Davidson D, Gulliver SB, Longabaugh R, Wirtz PW, Swift R. (2007) Building better cognitive-behavioral therapy: is broad-spectrum treatment more effective than motivational-enhancement therapy for alcohol-dependent patients treated with naltrexone? *J Stud Alcohol Drugs.* 68(2):238-47.
92. Davidson D, Gulliver SB, Longabaugh, R, Wirtz P, Swift R. (2007). Effect of 3 & 6 Mos. Of Treatment with Naltrexone (NTX) & Broad Spectrum Therapy (BST) or Motivational Enhancement Therapy (MET) on Drinking. *Alcohol Clin Exp Res*, 31(6) suppl.
93. Swift R, Oslin D, Alexander M, Forman R. (2007). Literature Review of Adherence Monitoring in Clinical Trials of Naltrexone for Alcohol Dependence. *Alcohol Clin Exp Res*, 31(6) suppl.
94. Tidey J, Monti P, Rohsenow D, Gwaltney C, Miranda, Jr. R, MacKillop J, McGeary J, Swift R., Abrams DB, Schiffman S, Paty JA (2008). Moderators of Naltrexone's Effects on Drinking, Urge and Alcohol Effects in the Natural Environment. *Alcohol Clin Exp Res*, 32(1):58-66.
95. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, (and in alphabetical order), Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM for the Topiramate for Alcoholism Advisory Board and the Topiramate for Alcoholism Study Group (2007). Topiramate for treating alcohol dependence: a randomized controlled trial. *JAMA*, 14:1641-1651.
96. Anton RF, Oroszi G, O'Malley SS, Couper D, Swift R, Pettinati H, Goldman G. Mu. (2008) Opiate Receptor (OPRM1) 118 Allele Variant and Naltrexone Response: Results from the COMBINE Study. *Arch General Psychiatry*, 65(2): 135-144.
97. Leggio L, Kenna GA, Swift RM. (2008). New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. *Progress in Neuropsychopharmacology & Biological Psychiatry*, 32(5):1106-1117.
98. Rohsenow DJ, Tidey J, Miranda R, McGeary JE, Swift RM, Hutchison KE, Sirota AD, Monti PM. (2008). Olanzapine Reduces Urge to Smoke and Nicotine Withdrawal. *Exp and Clin Psychopharmacology*, 16(3):215-222.
99. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Addolorato G, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM, for the Topiramate for Alcoholism Advisory Board and the Topiramate for Alcoholism Study Group (2008) Improvement of Physical Health and Quality of Life of Alcohol-Dependent Individuals with Topiramate Treatment: US Multisite Randomized Controlled Trial. *Arch Intern Med.* 168(11):1188-1199.
100. Leggio L, Ferrulli A, Cardone S, Miceli A, Kenna GA, Gasbarrini G, Swift RM, Addolorato G. (2008) Renin and aldosterone but not the natriuretic peptide correlate with obsessive craving in medium-term abstinent alcohol-dependent patients: a longitudinal study. *Alcohol.* 42(5):375-81

101. Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda R Jr, McGeary JE, MacKillop J, Swift RM, Abrams DB, Shiffman S, Paty JA (2008). Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. *Alcohol Clin Exp Res*, (1):58-66.
102. Miranda R Jr, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, Swift R, Ray L, McGeary J. (2008) Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. *Alcohol Clin Exp Res*. 32(3):489-97.
103. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Adolfo AB (2008). Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia and controls. *Nicotine Tob Res*. 10(6):1047-56.
104. Leggio L, Kenna GA, Swift RM. (2008) New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 32:1106-1117,
105. Ray LA, Hutchison KE, MacKillop J, Miranda R, Audette A, Swift RM, Monti M. (2008). Effects of Naltrexone During the Descending Limb of Blood Alcohol Curve. *American Journal on Addictions*, 17: 257–264,
106. Rohsenow DJ, Tidey JW, Miranda R, McGeary JE, Swift RM, Hutchison KE, Sirota AD, Monti PM. (2008) Olanzapine reduces urge to smoke and nicotine withdrawal symptoms in community smokers. *Exp Clin Psychopharmacol*. 16(3):215-22.
107. Leggio L, Ferrulli A, Cardone S, Malandrino N, Mirijello A, D'Angelo C, Vonghia L, Miceli A, Capristo E, Kenna GA, Gasbarrini G, Swift RM, Addolorato G. (2008) Relationship between the hypothalamic-pituitary-thyroid axis and alcohol craving in alcohol-dependent patients: a longitudinal study. *Alcohol Clin Exp Res*. 32(12):2047-53
108. Dumett M, Rosen G, Sabat J, Shaman A, Tempelman L, Wang C, Swift R. (2008) Deconvolving an Estimate of Breath Measured Blood Alcohol Concentration from Biosensor Collected Transdermal Ethanol Data. *Appl Math Comput*. 1;196(2):724-743.
109. Friedmann PD, Rose JS, Swift R, Stout RL, Millman RP, Stein MD. (2008). Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial. *Alcohol Clin Exp Res* 32(9):1652-60.
110. Weiss RD, O'Malley SS, Hosking JD, Locastro JS, Swift R; COMBINE Study Research Group (2008). Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study. *J Stud Alcohol Drugs*. 69(6):878-84.
111. Leggio L, Kenna GA, Fenton M, Bonenfant E, Swift RM. (2009) Typologies of alcohol dependence. From jellinek to genetics and beyond. *Neuropsychol Rev*. 19(1):115-29.
112. Kenna GA, Zywiak WH, McGeary JE, Leggio L, McGeary C, Wang S, Grenga A, Swift RM (2009). A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. *Alcohol Clin Exp Res* 33(2):315-23.
113. Oroszi G, Anton RF, O'Malley S, Swift R, Pettinati H, Couper D, Yuan Q, Goldman D. (2009) OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. *Alcohol Clin Exp Res*. 33(3):383-93.
114. Ray LA, Miranda R Jr, MacKillop J, McGeary J, Tidey JW, Rohsenow DJ, Gwaltney C, Swift RW, Monti PM (2009). A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. *Exp Clin Psychopharmacol*. 17(2):122-9.
115. Kenna GA, Leggio L, Swift RM. (2009) A Safety and Tolerability Laboratory Study of the Combination of Aripiprazole and Topiramate in Volunteers who Drink Alcohol. *Human Neuropsychopharmacol: Clinical and Experimental*, 24(6):465-72.
116. Leggio L, Ray LA, Kenna GA, Swift RM (2009). Blood Glucose Level, Alcohol Heavy Drinking and Alcohol Craving. Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study. *Alcohol Clin Exp Res* 33(9):1539-44.

117. Kenna GA, Lomastro TL, Schiesl A, Leggio L and Swift RM (2009). Review of Topiramate: An Antiepileptic for the Treatment of Alcohol Dependence. *Current Drug Abuse Reviews* 2:135-142.
118. Fenton M, Leggio L, Kenna GA, Swift RM (2010) HIV Testing in Hazardous Drinking: A Survey Analysis *Substance Use & Misuse* 45(1-2):204-212.
119. MacKillop J, Miranda R Jr, Monti PM, Ray LA, Murphy JG, Rohsenow DJ, McGeary JE, Swift RM, Tidey JW, Gwaltney CJ. (2010) Alcohol demand, delayed reward discounting, and craving in relation to drinking and alcohol use disorders. *J Abnorm Psychol.* 119(1):106-14.
120. Sirota AD, Rohsenow DJ, MacKinnon SV, Martin RA, Eaton CA, Kaplan GB, Monti PM, Tidey JW, Swift RM (2010) Intolerance for Smoking Abstinence Questionnaire: Psychometric properties and relationship to tobacco dependence and abstinence. *Addictive Behaviors* 35(7):686-693.
121. Ray LA, Miranda R Jr, Tidey JW, McGeary JE, MacKillop J, Gwaltney CJ, Rohsenow DJ, Swift RM, Monti PM. (2010) Polymorphisms of the micro-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment. *J Abnorm Psychol* 119(1):115-25.
122. Swift R (2010). Medications acting on the dopaminergic system in the treatment of alcoholic patients. *Current Pharm Design* 16(19):2136-40.
123. Leggio L, Cardone S, Ferrulli A, Kenna GA, Diana M, Swift RM, Addolorato G (2010). Turning the clock ahead: potential preclinical and clinical neuropharmacological targets for alcohol dependence. *Current Pharm Design* 16(19):2159-81.
124. Capone C, Kahler CW, Swift RM, O'Malley SS (2011) Does family history of alcoholism moderate naltrexone's effects on alcohol use? *J Stud Alcohol Drugs.* 72(1):135-40.
125. Leggio L, Addolorato G, Cippitelli A, Jerlhag E, Kampov-Polevoy AB, Swift RM (2011) Role of feeding-related pathways in alcohol dependence: A focus on sweet preference, NPY, and ghrelin. *Alcohol Clin Exp Res*, 35(2): 194-202.
126. Leggio L, Ferrulli A, Cardone S, Nesc Ai, Miceli A, Malandrino N, Capristo E, Canestrelli B, Monteleone P, Kenna GA, Swift RM, Addolorato G. Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving. *Addiction Biology*, 2011 (epub Mar).
127. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Reid N. Edwards S, Kenna GA, Swift RM, Leggio L. Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review. *Curr Pharm Des.* 2011;17(14):1323-32.
128. Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. *Psychopharmacology (Berl)*. 2011 Sep;217(2):279-87. Epub 2011 Apr 8.
129. Barnett NP, Tidey J, Murphy JG, Swift R, Colby SM. Contingency management for alcohol use reduction: A pilot study using a transdermal alcohol sensor. *Drug Alcohol Depend.* 2011 Jun 10. [Epub ahead of print]

BOOKCHAPTERS / BOOK REVIEWS

1. Swift RM (1987). The profound disability of substance abuse. In D Cone & D Galamaga (Eds.), *Disability Unbound*.
2. Swift RM (1987). Alcohol and drug abuse in the medical setting. In A Stoudemire & B Fogel (Eds.), *Principles of Medical Psychiatry*. Orlando, FL: Grune and Stratton.
3. Swift RM (1990). Alcohol and Drug Abuse. In A Stoudemire (Ed.), *Clinical Psychiatry for Medical Students*. Philadelphia: Academic Press.

4. Swift RM (1990). Review of Cocaine: The great white plague. *New Eng J Med*, 22(23), 1677.
5. Miller NS & Swift RM (Eds.). (1990). Addictive Disorders. *Psychiatric Clinics of North America*, Vol 22. Philadelphia: Saunders.
6. Swift RM, Camara P & Griffiths W. (1991). Laboratory testing for illicit drugs. In A Stoudemire & B Fogel (Eds.), *Medical Psychiatric Practice*. Washington DC: APA Press.
7. Swift RM & Swette L. (1992). Assessment of Alcohol Consumption with a wearable electronic ethanol sensor recorder. In Litten R & Allen J (Eds.), *Measuring Alcohol Consumption, Psychosocial and Biological Methods*. Totowa, NJ: Humana Press.
8. Swift RM (1992). Alcohol and drug abuse in the medical setting. In A Stoudemire & B Fogel (Eds.), *Principles of Medical Psychiatry* (2d ed.). Orlando, FL: Grune and Stratton.
9. Swift RM (1994). Alcohol and drug abuse. In A Stoudemire (Ed.), *Clinical Psychiatry For Medical Students* (2d ed.). Philadelphia: Lippencott.
10. Swift RM (1994). Review of Marijuana: The forbidden medicine. *New Eng J Med*, 331(11), 749-80.
11. Swift RM (1997). Treatment of addictive disorders. In NS Miller, MS Gold & DE Smith (Eds.), *Manual of Therapeutics for Addictions*. New York: Wiley-Liss.
12. Swift RM (1997). Pharmacological treatment of alcoholism: Clinical management. In N. Miller (Ed.), *Principles and Practice of Addictions in Psychiatry*. Philadelphia: Saunders.
13. Miller NS & Swift RM (1997). Primary care medicine and psychiatry: Addictions treatment. *Psychiatric Annals*, 27(6), 408-416.
14. Swift RM (1997). Review of Biological aspects of alcoholism. *J Subst Abuse Treat*, 14(2), 200-201.
15. Swift RM (1997). Review of suicide in alcoholism. *Substance Abuse*, 17(4), 241-242.
16. Swift RM (1998). Alcoholism and Substance Abuse. In Stoudemire A (Ed.), *Clinical Psychiatry for Medical Students* (3d ed.). Philadelphia: Lippincott-Raven.
17. Swift RM, Lewis DC & Miller NS. (1998). Addictive Disorders. In Goldman LS, Wise TN, Brody DS (Eds.), *Psychiatry for Primary Care Physicians*. Chicago: American Medical Association Press.
18. Swift RM(1999). Clonidine in the treatment of substance withdrawal syndromes. In G Adelman & B Smith (Eds.). *Encyclopedia of Neuroscience* (2d ed.), (pp. 409-410). Netherlands: Elsevier Science.
19. Swift RM (1999). Alcohol and drug abuse in the medical setting. In A Stoudemire, B Fogel & D Greenberg (Eds.), *Psychiatric Care of the Medical Patient* (2d ed.). Oxford U. Press.
20. Swift RM (1999). Alcohol and drug dependence: Drug delivery to treatment. In E Mathiowitz (Ed.), *The Encyclopedia of Controlled Drug Delivery*. New York: John Wiley.
21. Swift RM & Mueller T. (2001). Treatment of anxiety in substance abuse and dependence. In J Hubbard and P Martin (Eds.), *Addictive disorders in the mentally and physically disabled*. Marcel Dekker.
22. Swift RM (2002). Medications in the treatment of alcohol dependence. In R Hester and W Miller (Eds.), *Handbook of alcoholism treatment approaches: Effective alternatives*, (3d ed.). Boston: Allyn & Bacon.
23. Swift RM (2004). Emergency management of alcohol and drug abuse. In Johnson B, Ruiz P, Galanter M (eds). *Handbook of Clinical Alcoholism Treatment*. Lippincott Williams Wilkins.
24. Kenna GA, Swift RM, Agath K (2008). The Pharmacotherapy of Alcohol Misuse, Dependence and Withdrawal in K. Silk and K. Brower (ed) *Cambridge Handbook of Effective Treatments in Psychiatry*. Cambridge U. Press.
25. Swift RM, Leggio L. (2009) Adjunctive Pharmacotherapy in the Treatment of Alcohol and Drug Dependence. In P.M. Miller (ed). *Evidence Based Addiction Treatment*. Academic Press

NON PEER-REVIEWED PUBLICATIONS

1. Miller NS, Swift RM & Gold MS. (1998). Health care economics for integrated addiction treatment in clinical settings. *Psychiatric Annals*, 28(12), 682-689.
2. Swift RM (1998). Pharmacologic treatments for drug and alcohol dependence: Experimental and standard therapies. *Psychiatric Annals*, 28(12), 697-702.
3. Swift RM (2000). Opioid antagonists in the treatment of alcohol dependence. *Psychiatric Spectrums* 5(2), 49-57.
4. Swift RM (2001). The pharmacotherapy of alcohol dependence: Clinical and economic aspects. *The Economics of Neuroscience*, 3(12), 1-5.
5. Swift RM (2001). Medications for the treatment of alcohol dependence. *Psychopharmacology Update*, 12, 12.
6. Kenna G & Swift RM (2004). Pharmacotherapies for Alcohol Dependence. *U.S. Pharmacist*. February 93-103.

CORPORATE AUTHORSHIP OR MULTICENTER TRIALS

1. Anton RF, Lieber C, Tabakoff B, for the CDTect Study Group. (2002) Carbohydrate deficient transferrin (CDT) and gamma-glutamyltransferase for the detection and monitoring of alcoholics. Results from a multi-site study. *Alcoholism: Clin Exp Research*, 26(8):1215-1222.
2. Combine Study Research Group (2003). Testing combined pharmacotherapies and behavioral interventions in alcohol dependence (The COMBINE Study): a pilot feasibility study, *Alcoholism: Clin Exp Research*, 27(7):1123-31.
3. Combine Study Research Group (2003). Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. *Alcoholism: Clin Exp Research*, 27(7):1107-22.
4. Kranzler HR, Wesson DR, Billot L, for the Drug Abuse Sciences Naltrexone Depot Study Group. (2004) Naltrexone depot for the treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. *Alcoholism: Clin Exp Research*, 28(7):1051-59.
5. Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCaul ME, Anthenelli R, Salloum I, Galloway G, Garbutt J, Swift R, Gastfriend D, Kallio A, Karhuvaara S. (2004) A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. *J Clin Psychopharmacol*. 24(4):421-8.
6. Zarkin GA, Bray JW, Aldridge A, Mitra D, Mills MJ, Couper DJ, Cisler RA, and COMBINE Cost-Effectiveness Research Group (2008). Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients. *Arch Gen Psychiatry*. 65(10):1214-21.

PUBLICATIONS SUBMITTED OR IN PRESS

1. Swift RM, Oslin DW, Alexabder M, Forman R. Adherence Monitoring in Naltrexone Pharmacotherapy Trials: A Systematic Review. *J Studies Alcohol Drugs* (In press)

ABSTRACTS

1. Swift RM & Hoffmann PC. (1977). Acute effect of lateral hypothalamic lesions on the utilization of GABA in the striatum and substantia nigra of the rat brain. *Fed Proc*, 36(3), 951.
2. Swift RM, Bernstein JE, Soltani K & Lorincz. A. (1979). Inhibition of axon reflex vasodilatation in human skin by topical applied Capsaicin. *Clin Research*, 27(2), 245A.
3. Deyo S, Swift R & Miller RJR. (1979). Endorphins and morphine modulate hypothalamic dopamine metabolism. *Fed Proc*, 38(1), 364.

4. Bernstein JE, Swift R, Soltani K & Lorincz A. (1980). Suppression of histamine-induced pruritus by N-allylnoroxymorphone. *Clin Research*, 28, 247A.
5. Swift RM, Mirassou M, Schwartz J & Leigh H. (1982). Strategies for the treatment of chronic pain in drug dependent patients. Am Acad Psychosomatic Med Meeting, Chicago.
6. Swift RM, DePetrillo P, Brown WA, Liepman, M & Nirenberg T. (1986). Human lymphocyte beta-adrenergic activity in ethanol withdrawal. Proceedings at ACNP Meeting.
7. Swift RM & DePetrillo P. (1986). Effect of Ethanol on Human Mononuclear Cell Cyclic AMP Formation. *Clin Research*, 34(2), 407A.
8. Swift RM, Marlink R & Foss B. (1987, November). AIDS education and testing in a drug abuse treatment program. Presented at AMERSA National Conference, Washington, DC.
9. Marlink R, Foss B, Swift R, et al. (1987). High Rate of Exposure to HIV in a Small Sized City and the Use of Methadone Maintenance to Educate and Reduce High Risk Behavior Proceedings at Third International Conference on AIDS.
10. Swift RM, DePetrillo P, Dudley M, Griffiths W & Dextraze P. (1987). Altered methadone pharmacokinetics in pregnancy with twins. *Clin Pharm Ther*, 41(2), 231.
11. Swift RM, DePetrillo P & Sullivan J. (1988). An open study of Clonidine detoxification in the general hospital. *Clin Pharmacol Ther*, 43(2), 186.
12. Swift RM, DePetrillo PB & Ambrose C. (1989, December). A Novel effect of Ethanol on Human Platelet Cyclic AMP. Proceedings of the ACNP Annual Meeting, Maui, Hawaii.
13. Liepman MR, Dube CE, Zwick WR, Wartenberg AA, Goldstein MG & Swift RM (1989, November). Measuring attitudes of health professionals towards substance abuse. Presented at AMERSA National Conference.
14. Stout RL & Swift RM (1989, June). Multivariate Modeling of Opiate Withdrawal Symptoms. Proceedings of the Society for Mathematic Psychology Annual Meeting.
15. Sullivan JT & Swift RM (1989). Relationship of admitting blood alcohol level to benzodiazepine requirements during alcohol detoxification. *Eur J Clin Pharmacol*.
16. Swift RM (1989, March). The relationship between craving and anxiety in opioid withdrawal. Proceedings of the WFSBP Conference on Non-psychotic Disorders, Jerusalem, Israel.
17. Swift R, Marlink R & Foss B. (1989, February). HIV Seropositivity and effectiveness of methadone maintenance treatment. Proceedings of AMSAODD Third National Forum on AIDS and Chemical Dependency, Miami, Fla.
18. Sullivan JT & Swift RM (1989). Benzodiazepine requirements during alcohol withdrawal: the influence of a standardized withdrawal scale. *Clin Pharm Ther*, 45(2), 130.
19. Liepman MR, Wartenberg AA, Swift RM & Nirenberg TD. (1989). Aspirin reversal of the disulfiram-ethanol reaction in man: a case study. *Alcohol Clin Exp Res*, 12.
20. Swift RM & DePetrillo PB. (1990, December). Ethanol inhibits cyclic AMP in isolated human platelets. Proceedings of the Am College Neuropsychopharm Annual Meeting, San Juan.
21. Swift RM & DePetrillo PB. (1990, November). Ethanol and platelet cyclic AMP. Presented at AMERSA National Meeting, Rockville, MD.
22. Mueller, TI & Swift RM (1990, November). The AIDS Questionnaire: A Rapid Screening device for risk of exposure to HIV. Presented at AMERSA National Meeting, Rockville, MD.
23. Swift RM & DePetrillo P. (1990). Ethanol and Human Platelet Cyclic AMP. *Alcohol Clin Exp Res*, 14(2), 343.
24. Swift R, Martin C, Swette L, LaConti A & Kackley N. (1991). Clinical studies of a wearable transdermal alcohol sensor. *Alcohol Clin Exp Res*, 15(2).
25. Swift R, Whelihan W, Kuznetsov O & Hsiung H. (1992, December). Effect of naltrexone on ethanol intoxication in humans. Presented at the ACNP Annual Meeting San Juan.

26. Swift R, Whelihan W, Kuznetsov O & Hsiung H. (1992, November). Effect of naltrexone on ethanol intoxication in non-alcoholic humans. Presented at AMERSA National Meeting, Bethesda, MD.
27. Swift R, Kuznetsov O, Swette L & Martin C. (1992). Relative contributions of diffusion and sweat to transdermal ethanol. *Alcohol Clin Exp Res*, 16(2), 374.
28. Swift RM, Swette L & LaConti A. (1992). Transdermal ethanol measurement of blood alcohol concentration. *Alcoholism*, 27(Suppl. 1), 43.
29. Whelihan WM, Swift RM, Daamen M & Hedeem C. (1992). Effects of D4T on neuropsychological functioning. Presented at III International Conference on AIDS, Amsterdam.
30. Martin C, Earleywine M, Musty R, Perrine M & Swift R. (1992). Development & validation of the biphasic alcohol effects scale. *Alcohol Clin Exp Res*, 16(2), 417.
31. Swift RM, Love C, Marlink R & Foss B. (1992). HIV Seropositivity and effectiveness of methadone maintenance treatment. NIDA Research Monograph, 119:304.
32. Nirenberg T, Swift R, Sirota A, Wartenberg A & Depetrillo P. (1992). Prevalence of THC Use in a Methadone Clinic, NIDA Research Monograph, 119:457.
33. Swift R, Whelihan W & Kuznetsov O. (1993). Naltrexone effect on experimental ethanol intoxication. *Alcohol Clin Exp Res*, 17(2), 460.
34. Swift R, Kuznetsov O & Whelihan W. (1994). Ondansetron modifies human ethanol intoxication. *Alcohol Clin Exp Res*, 18(2), 211.
35. Swift RM & Davidson. (1995). Naltrexone reduces urge to drink in social drinkers. Presented at the ACNP Annual Meeting San Juan PR.
36. Swift RM, Duncan D & Nirenberg TD. (1995). Patients' attitudes on pharmacotherapies for alcoholism. *Alcohol Clin Exp Res*, 19(2)Suppl. 16A.
37. Swift RM, Davidson D, Nirenberg TD & Lai N. (1995). Effect of gender on transdermal ethanol. *Alcohol Clin Exp Res*, 19(2)Suppl. 42A.
38. Swift R, Davidson D & Lai N. (1995). Effect of the alpha-2-antagonist idazoxan on human alcohol intoxication. *Alcohol Clin Exp Res*, 19(2)Suppl. 68.
39. Swift RM, Davidson D, Rosen S & Fitz E. (1996). Naltrexone pretreatment enhances diazepam intoxication in social drinkers. *Alcohol Clin Exp Res*, 20(2)Suppl. 109.
40. Davidson D & Swift RM (1996). Relationship between the stimulant subscale of the biphasic alcohol effects scale, alcohol pharmacokinetics and the alcohol sensation scale. *Alcohol Clin Exp Res*, 20(2)Suppl. 40A.
41. Davidson D, Swift RM & Fitz E. (1996). Naltrexone pretreatment decreases urge to drink alcohol in social drinkers. *Alcohol Clin Exp Res*, 20(2)Suppl. 44A.
42. Swift RM, Davidson D & Fitz E. (1996). Transdermal alcohol detection with a new miniaturized sensor, the MiniTAS. *Alcohol Clin Exp Res*, 20(2)Suppl. 45A.
43. Monti PM, Rohsenow DJ, Swift RM, Abrams DB, Colby SM, Mueller TI, Brown RA & Gordon A. (1996). Effect of naltrexone on urge to drink during alcohol cue exposure: Preliminary results: *Alcohol Clin Exp Res*, 20(2)Suppl. 92A.
44. Swift RM, Davidson D & Lai N. (1996). Effects of the alpha-2-antagonist idazoxan on ethanol intoxication in social drinkers. *Alcohol Clin Exp Res*, 20(2)Suppl. 108A.
45. Davidson D, Swift RM & Fitz E. (1996). Naltrexone decreases urge to drink alcohol in social drinkers. New Research Poster, APA Annual Meeting, New York. May.
46. Swift R & Davidson D. (1997). Effect of family history on subjective alcohol intoxication. *Alcohol Clin Exp Res*, 21(3), 464A.
47. Swift R & Davidson D. (1997). Pharmacokinetic and behavioral effects of low dose intravenous administered alcohol in humans. *Alcohol Clin Exp Res*, 21(3), 465A.

48. Davidson D & Swift RM (1997). Quantifying psychomotor stimulant effects of alcohol on movement in humans. *Alcohol Clin Exp Res*, 21(3), 460A.
49. Davidson D & Swift RM (1997). Quantifying psychomotor stimulant effects of alcohol on speech production in humans. *Alcohol Clin Exp Res*, 21(3), 461A.
50. Swift R & Davidson D. (1997). A field trial of transdermal alcohol for measurement of consumption. *Alcohol Clin Exp Res*, 21(3), 546A.
51. Rohsenow DJ, Monti PM, Swift RM, Abrams DB, Colby SM, Mueller TI, Brown RA, Gordon A & Martin RA. (1997). Predictors of medication compliance in a 12-week naltrexone trial among alcoholics. *Alcohol Clin Exp Res*, 21(3), 755A.
52. Swift R & Davidson D. (1998). Reasons for non-compliance in naltrexone clinical trials. Presented at the Canadian College of Neuropsychopharmacology Meeting, Montreal, CA.
53. Davidson D, Palfai T, Bird C & Swift R. (1998). The effect of naltrexone on craving for alcohol and alcohol consumption following cue exposure in problem drinkers. *Alcohol Clin Exp Res*, 22(3), 396A.
54. Davidson D, Palfai T, Bird C & Swift R. (1998). The effect of naltrexone on *ad libitum* alcohol intake, mood and craving in female social drinkers: preliminary analyses. *Alcohol Clin Exp Res*, 22(3), 658A.
55. Hutchison K, Swift R, Attias E & Davidson D. (1998). Effects of olanzepine on alcohol-induced stimulation: preliminary results. *Alcohol Clin Exp Res*, 22(3), 661A.
56. Hutchison KE, Swift R, Attias E, Monti P & Rohsenow D. (1998). Effects of olanzepine on cue-induced craving in moderate to heavy social drinkers. *Alcohol Clin Exp Res*, 22(3), 662A.
57. Swift R, Bird C, Santa Ines M, Almeida A & Davidson D. (1999). A comparison of transdermal alcohol detection and self-report for determining alcohol consumption. *Alcohol Clin Exp Res*, 23(5), 741A.
58. Davidson D, Hutchison K, Dagon C & Swift R. (1999). Quantifying alcohol reinforcement in humans. *Alcohol Clin Exp Res*, 23(5), 419A.
59. Swift RM & Swette L. (2000, December). A wearable transdermal wrist sensor for estimation of blood alcohol levels. Presented at the ACNP Annual Meeting San Juan, Puerto Rico.
60. Swift RM (2000). Transdermal measurement of alcohol drinking. *Brit J Clinical Pharmacology* (CPT Abstracts) 113, 425.
61. Swift RM, Kaplan G & Eslami A. (2001, December). Effect of the protein kinase C inhibitor tamoxifen on human alcohol intoxication. Presented at the ACNP Annual Meeting Kilo HI.
62. Rohsenow D, Monti P, Swift R, Gulliver S, Colby S, Mueller T, Brown R, Gordon A & Niaura R. (2001). Naltrexone, cue exposure and communication skills training: effects on 1-year outcomes. *Alcohol Clin Exp Res*, 25(5), Suppl. 144A.
63. Swift R, Santa Ines M & Davidson D. (2001). Transdermal alcohol detection vs. self report for determining alcohol drinking. *Clinical Pharmacology and Therapeutics*, 69(2), P61.
64. Swift R, Wieland S, Smoger S, Blondell R, Sexton L, Looney SW & Rhodes S. (2001). Hospital Use of Ethanol Survey (HUES) *Journal of Addictive Diseases*, 20(2), 179.
65. Thomas C, Wallack S, Swift R, Bishop C, McCarty D & Simoni-Wastila L. (2001). Adoption of naltrexone in alcoholism treatment. *Journal of Addictive Diseases*, 20(2), 180.
66. Zywiak W, Stout R, Trefry W, LaGrutta J, Swift R. (2002) Alcohol relapses associated with September 11. *Alcohol Clin Exp Res*, 26(5) suppl. 151A.
67. Gulliver SB, McAdoo G, Davidson D, Longabaugh R, Swift R. (2002) Training addiction counselors in broad-spectrum therapy. *Alcohol Clin Exp Res*, 26(5) suppl. 199A.
68. Smoger S, Looney SW, Dodds HN, Blondell R, Sexton L, Swift R (2002). Hospital Use of Ethanol Study (HUES) Results *Alcohol Clin Exp Res*, 26(5) suppl. 472A.
69. Rosen G, Wang C, Caflisch R, Swette L, Swift R (2002). Mathematical modeling and deconvolution of blood alcohol level from transdermal alcohol measurements. *Alcohol Clin Exp Res*, 26(5) suppl. 1085A.

70. Pierucci-Lagha A, Feinn R, Swift R.M., Nellissery M, , Covault J. Kranzler HR, The effects of rapid tryptophan depletion on mood and urge to drink in alcoholics with comorbid major depression. (2003) *Alcohol Clin Exp Res*, 27(5) suppl. 101A.
71. Swift R.M., Karolczuk K, Eslami A., Tempelman L. (2003). A miniaturized transdermal alcohol sensor: a progress report. *Alcohol Clin Exp Res*, 27(5) suppl. 157A.
72. McGeary, JE, Monti, PM, Rohsenow, DJ, Tidey, J, Swift R. (2004, Sep-Oct). The DRD4 Gene and Cue-induced Alcohol Craving in a Naltrexone Trial: Preliminary Results. Poster presented at the ISBRA 12th World Congress on Biomedical Alcohol Research, Heidelberg/Mannheim, Germany.
73. Swift, RM, Tempelman L, Rosen, G. (2004, Sep-Oct). A Wearable Transdermal Alcohol Sensor for Measurement of Alcohol Drinking. Poster presented at the ISBRA 12th World Congress on Biomedical Alcohol Research, Heidelberg/Mannheim, Germany.
74. Swift, RM (2004, Sep-Oct). A Perspective from US Clinical Practice. Poster presented at the ISBRA 12th World Congress on Biomedical Alcohol Research, Heidelberg/Mannheim, Germany.
75. Monti, PM, Rohsenow D, Tidey, J, McGeary J., Swift, R. (2004, Sep-Oct). Naltrexone Craving for Alcohol and Drinking: Laboratory and Ecological Assessments. Poster presented at the ISBRA 12th World Congress on Biomedical Alcohol Research, Heidelberg/Mannheim, Germany.
76. Greeley, H, Swift, R, MacAskill, H, Eslami, A, Berg, J, Frits, E. (2005, June). Quantification of Alcohol Impairment by Voice Analysis. Presented at the 28th Annual Meeting of the Research Society on Alcoholism, Santa Barbara, California.
77. Rosen LG, Cafflisch, R, Dumett, M, Sabat J, Shaman, A, Tempelman, L, Wang, C, Wang, T, Swift, R. (2005, June). Mathematical Models for the Pharmacokinetics and Transport of Transdermal Alcohol. Presented at the 28th Annual Meeting of the Research Society on Alcoholism, Santa Barbara, California.
78. McGeary, JE, Monti, PM, Rohsenow, DJ, Tidey, J, Swift, R. (2005, June). MU-Opiate Receptor Gene Polymorphism Moderates Naltrexone's Effects on Cue Reactivity in Non-Treatment Seeking Heavy Drinkers. Presented at the 28th Annual Meeting of the Research Society on Alcoholism, Santa Barbara, California.
79. McGarvey, ST, Swift, RM, McGeary, JE, Deka, R. (2005, June). Prevalence of Alcohol Use and Alcohol Genes in Samoans. Presented at the 28th Annual Meeting of the Research Society on Alcoholism, Santa Barbara, California.
80. Swift, R, MacAskill, H, Eslami, A, Tempelman, L, Rosen, G, Cafflisch, R, Wang, C, Feinberg, J. (2005, June). Skin Factors Affecting the Pharmacokinetics of Transdermal Alcohol. Presented at the 28th Annual Meeting of the Research Society on Alcoholism, Santa Barbara, California.
81. Swift, RM, Kenna, GA, Eslami, A. (2005, June). Alcohol Administration to Volunteers Taking Tamoxifen: A Pilot Study. Presented at the 28th Annual Meeting of the Research Society on Alcoholism, Santa Barbara, California.
82. Davidson, D, Gulliver, S, Longabaugh, R, Wirtz, P, Swift, R. (2006, June). Building Better Cognitive Behavioral Therapy. Presented at the 29th Annual Meeting of the Research Society on Alcoholism, Baltimore, MD.
83. Davidson, D, Gulliver, S, Longabaugh, R, Wirtz, P, Swift, R. (2006, June). Alcoholism Treatment: Identifying Naltrexone Responders. Presented at the 29th Annual Meeting of the Research Society on Alcoholism, Baltimore, MD.
84. Kenna, GA, Neilsen, D, DeCubellis, S, Swift, RM. (2007, April). The Adverse Events of Combining Aripiprazole and Topiramate with a Modest Amount of Alcohol. Submitted to the 10th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Colorado Springs, CO.
85. Swift RM, Oslin D, Alexander M, Forman RF (2007, May). A literature review of adherence monitoring in clinical trials of naltrexone for alcohol dependence. New Research Poster Presented at the American Psychiatric Association Annual Meeting, San Diego CA,

86. Kenna, GA, Nielsen, D, DeCubellis, S, Swift, RM. (2007, June). The Safety and Tolerability of Combining Aripiprazole and Topiramate with Alcohol. Submitted to the 69th Annual Scientific Meeting of the College of Drug Dependence, Quebec, Canada.
87. Sirota, A, Rohsenow DJ, MacKinnon S, Martin R, Kaplan G, Monti PM, Almeida A, Tidey J, Swift R. (2007, June). Tolerance for smoking discomfort: A new questionnaire of ability to handle nicotine withdrawal and cravings. Poster presented at the 69th Annual Scientific Meeting of the College of Drug Dependence, Quebec, Canada.
88. Kenna, GA, Neilsen, D, DeCubellis, S, Swift, RM. (2007, June). A Pilot Lab Study of the Safety of Aripiprazole and Topiramate Combined with Alcohol. Submitted to the 11th Annual Research Symposium on Mental Health Sciences, Butler Hospital, Providence, RI.
89. Kenna, GA, DeCubellis, S., Swift, RM. (2007, June). Mismatching and Mismatching Serotonergic Medications with 5-HTTLPR Alleles for the Treatment of Alcohol Dependence. Submitted to the 47th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL.
90. Davidson, D, Gulliver, SB, Longabaugh, R, Wirtz, P, Swift, R. (2007, July). Effect of 3 & 6 Mos of Treatment with Naltrexone (NTX) & Broad Spectrum Therapy (BST) or Motivational Enhancement Therapy (MET) on Drinking. Presented at the 30th Annual Meeting of the Research Society on Alcoholism, Chicago, IL.
91. Tidey, J, Monti, P, Rohsenow, D, Gwaltney, C, Miranda, Jr. R, McGeary, J, MacKillop, J, Swift, R. (2007, July) Naltrexone's Effects on Drinking in the Natural Environment: Mediators and Moderators. Presented at the 30th Annual Meeting of the Research Society on Alcoholism, Chicago, IL.
92. Swift R, Oslin D, Alexander M, Forman R. (2007, July). Literature Review of Adherence Monitoring in Clinical Trials of Naltrexone for Alcohol Dependence. Presented at the 30th Annual Meeting of the Research Society on Alcoholism, Chicago, IL.
93. Gogineni A, Swift R, McCaul M. (2007, July). Alcohol & Other Substance Use, HIV Risk Behaviors & Perceived Social Support among Injection Drug Users with STD's. Presented at the 30th Annual Meeting of the Research Society on Alcoholism, Chicago, IL.
94. Rosen G, Piterbarg Y, Dumett M, Schumitzky A, Tempelman L, Swift R. (2007, July). A Population Analysis Based Approach for Estimating Blood Alcohol Concentration from the Transdermal Ethanol. Presented at the 30th Annual Meeting of the Research Society on Alcoholism, Chicago, IL.
95. Anton R, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D (2007, July). Variation in the MU-Opiate Receptor Gene (OPRM1) Predicts Response to Naltrexone: Results from the COMBINE Study. Presented at the 30th Annual Meeting of the Research Society on Alcoholism, Chicago, IL.
96. Swift, RM, Valko L, Zambre R, Tempelman L, DeCubellis S, Grenga A, Moeller P, Krebs, WM, Schmitt EW (2007, July). A Wireless Electrochemical Transdermal Alcohol Sensor. Presented at the 30th Annual Meeting of the Research Society on Alcoholism, Chicago, IL.
97. Kenna, GA, Mello, P, Charpentier, M, Fisher, K, Swift, RM, Femino, J, Letendre, D, Lausier, J, DeCubellis, S, Pritchard B (2007, November). A Symposium to Facilitate Substance Abuse Education into the Curriculum at a Northeast College of Pharmacy. Presented at the 31st Annual Conference of the Association for Medical Education and Research on Substance Abuse, Baltimore, MD.
98. Grenga A, DeCubellis S, McGeary J, McGeary C, Zywiak W, Sorsa K., Tavares T, Kenna GA, Swift RM (2008, March). A Randomized Double-Blind Placebo-Controlled Pilot Study Matching and Mismatching Ondansetron and Sertraline based on 5-HTT Transporters in Non-Treatment Seeking Alcohol Dependent Participants. Presented at the 79th Meeting of the Eastern Psychological Association Conference, Boston MA.
99. Suorsa K, DeCubellis S, McGeary J, McGeary C, Zywiak W, Grenga A, Tavares T., Kenna GA., Swift RM (2008, March). The effects of Sertraline and Ondansetron on the Urge of Alcoholics to Drink. Presented at the 79th Meeting of the Eastern Psychological Association Conference, Boston MA.
100. Tavares T, DeCubellis S, McGeary J, McGeary C., Zywiak W, Grenga A., Sorsa K, Kenna GA, Swift RM (2008, March). The Relationship of Alcohol Craving to Ondansetron or Sertraline in a Double-Blind Placebo Controlled-Pilot Study of Non-Treatment Seeking Alcohol Dependent Individuals

Matched and Mis-Matched to 5-HTT Reuptake Transporters. Presented at the 79th Meeting of the Eastern Psychological Association Conference, Boston MA.

101. Kenna GA, DeCubellis S, McGeary J, McGeary C, Zywiak W, Grenga A, Tavares T, Sorsa K, Leggio L, Swift RM (2008, June). A Pilot Trial Matching Serotonergic Pharmacotherapies Based on 5-HTT Alleles in Alcohol Dependent Individuals. Abstract presented at the 31st Annual Meeting of the Research Society on Alcoholism, Washington DC.
102. Leggio L, Ferrulli A, Cardone S, Malandrino N, Mirijello A, D'Angelo C, Vonghia L, Miceli A, Capristo E, Kenna GA, Gasbarrini G, Swift RM, Addolorato G. (2008, June). A Longitudinal Study on the Relationship Between Alcohol Craving And The Hypothalamic-Pituitary-Thyroid And Volume-Regulating Hormones. Abstract presented at the 31st Annual Meeting of the Research Society on Alcoholism, Washington DC.
103. MacKillop J, Miranda R, JR, Monti PM, McGeary JE, Ray LA, Swift RM, Rohsenow DJ, Tidey JW, & Gwaltney C (2008). DRD4 VNTR and OPRM1 genotypes as moderators of alcohol cue reactivity and responses to alcohol. *Alcoholism: Clinical and Experimental Research*, 32 (Suppl.), 209A. Poster presented at the joint meeting of the Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism, Washington, DC; June, 2008.
104. Carter AC, Miranda R, JR, Gwaltney C, Tidey J, Rohsenow DJ, Swift R, & Monti PM (2010, June). Naltrexone's impact on alcohol expectancies in heavy drinkers. Poster presented at the annual meeting of the Research Society on Alcoholism, San Antonio, TX.
105. Monti P, Miranda R, JR, Justus A, MacKillop J, Meehan J, Tidey J, & Swift R. (2010, December). Biobehavioral mechanisms of topiramate and drinking in adolescents: Preliminary findings. Poster presented at the annual meeting of the American College of Neuropsychopharmacology, Miami, FL.
106. Rohsenow DJ, McGeary J, Tidey J, Martin R, Swift R, Miranda R, JR, Hutchison K, & Monti PM (2010, June). Effects of ondansetron and naltrexone on urge to drink before and after drinking are moderated by family history and DRD4 VNTR. In J. Kramer (Chair), *Craving: Its measurement, biological causes, and role in alcohol dependence*. Symposium conducted at the annual meeting of the Research Society on Alcoholism, San Antonio, TX.
107. Kenna GA, Zywiak W, McGeary J, McGeary C, Leggio L, Swift RM. Sedation, craving, and stimulation as mechanisms of action for ondansetron and sertraline to reduce heavy drinking. Poster presented at the 33th Annual Scientific Meeting of the Research Society on Alcoholism (RSA); San Antonio, TX, June 26-30, 2010; abstract in *Alcoholism: Clinical and Experimental Research*, 34(Suppl. 2): 174A, 2010.
108. Rohsenow DJ, McGeary J, Tidey J, Martin R, Swift R., Miranda R, & Monti P (2010, September). Effects of ondansetron and naltrexone on craving and mood before and after drinking are moderated by family history and DRD4 VNTR. Poster presented at the International Society of Biomedical Research on Alcoholism, Paris, France.
109. Miranda R, JR, Reynolds E, Meehan J, Justus A, Ramirez J, Tidey J, Monti P, Swift R, MacKillop J, & Chun T (2010, December). Biobehavioral mechanisms of naltrexone's action on drinking in adolescents: Preliminary findings. Poster presented at the annual meeting of the American College of Neuropsychopharmacology, Miami, FL.
110. Murphy CM, MacKillop J, Miranda R, JR., Meehan J, Swift RM, & Monti PM (2011, June). A dose-based meta-analysis of topiramate's effects on alcohol consumption and heavy drinking. Poster presented at the annual meeting of the Research Society on Alcoholism, Atlanta, GA.
111. Ray RA, Chin P, Heydari A, Swift R, Miotto K (2011, December). Mechanisms of action of quetiapine for alcohol dependence: a pilot study. Poster presented at the 49th Annual Meeting of the American College of Neuropsychopharmacology (ACNP); Miami, FL, December 5-9, 2010.
112. Swift RM, Kenna G, Leggio L, McGeary J, Zywiak W, Grenga A, Kim J, Ciminelli N. Relationship between the stimulant effects of alcohol and alcohol craving. Poster presented at the 49th Annual Meeting of the American College of Neuropsychopharmacology (ACNP); Miami, FL, December 5-9, 2010.

INVITED PRESENTATIONS—REGIONAL AND NATIONAL

1. Swift, R. (1984). Treatment of Chronic Pain and Substance Abuse. Grand Rounds, University of Chicago Department of Psychiatry, Chicago, IL.
2. Swift, R. (1984). Adolescent Suicide. Bradley Hospital Symposium Group Discussion Leader, Providence, RI.
3. Swift, R. (1984). Receptor Mediation of Alcohol and Drug Withdrawal Syndromes. Rhode Island Hospital General Hospital Psychiatry Lecture Series, Providence, RI.
4. Swift, R. (1985). Use of Antidepressants. Grand Rounds, Roger Williams General Hospital/Brown University Medical School, Providence, RI.
5. Swift, R. (1986). Use of Anti-anxiety Medication in Clinical Practice. Speaker, Cranston General Hospital Annual Meeting, Cranston, RI.
6. Swift, R. (1986). Use of Sedative and Hypnotics. Grand Rounds, St. Luke's Hospital, New Bedford, MA.
7. Swift, R. (1986, April). Roger Williams General Hospital/Brown University Symposium on Geriatric Psychopharmacology, Conference Organizer and Speaker, Providence, RI.
8. Swift, R. (1986, May). Adrenergic Nervous System Function in Alcohol and Drug States Seminar. National Institute of Drug Abuse, Addiction Research Center, Baltimore, MD.
9. Swift, R. (1987). AIDS and Substance Abuse. Speaker, Rhode Island Group Health Association (RIGHA), Providence, RI.
10. Swift, R. (1987). Mental Health Aspects of Substance Abuse. Roger Williams General Hospital Nursing Grand Rounds Speaker, Providence, RI.
11. Swift, R. (1987). Geriatric Psychopharmacology. Grand Rounds, Kent County Hospital, Warwick, RI.
12. Swift, R. (1987, April). Cocaine Abuse and Treatment. Newport Naval Hospital Seminar Series, Newport, RI.
13. Swift, R. (1987, April). Treatment of Opiate Abuse and Dependence. Speaker, Massachusetts Division of Substance Abuse Regulation Training Session. Lakeville, MA.
14. Swift, R. (1987, July). Mental Health Aspects of AIDS Seminar. Marathon House Community Outreach AIDS Project.
15. Swift, R. (1987, August). Medical Aspects of Methadone Maintenance. Speaker, Center for Behavioral Health Methadone Maintenance Program, Johnston, RI.
16. Swift, R. (1987, November). State of Rhode Island Department of Mental Health, Retardation and Hospitals Symposium on Brain Sciences and Related Information Sciences in Future Health Care. Reactor Panel on Substance Abuse Issues, Cranston, RI.
17. Swift, R. (1988, June). Geriatric Psychopharmacology. Lecturer, Corrigan Mental Health Center Annual Symposium on Psychopharmacology. Fall River, MA.
18. Swift, R. (1988, July). Mental Health Aspects of AIDS. Conference Speaker, National Institute of Drug Abuse House AIDS Community Outreach Project Training Session, Providence, RI.
19. Swift, R. (1988, July). AIDS and Substance Abuse. Speaker, Commonwealth of Massachusetts Mayors' Conference, Boston, MA.
20. Swift, R. (1988, October). Methadone Treatment in Pregnancy. Grand Rounds, Woman and Infants Hospital of Rhode Island Ambulatory Care.
21. Swift, R. (1988, November). AIDS and Substance Abuse Session. Symposium moderator, Association for Medical Education and Research (AMERSA) Annual Meeting, Washington, DC.
22. Swift, R. (1988, November). Use of Anxiolytic Medication, Teleconference Moderator. Providence, RI.
23. Swift, R. (1989, January). Benzodiazepines in General Medical Practice. Grand Rounds, Roger Williams General Hospital-Providence VA Medical Center Combined.

24. Swift, R. (1989, February). Cocaine Abuse. Roger Williams Hospital Nursing Grand Rounds.
25. Swift, R. (1989, May). Workshop Faculty, NIAAA/NIDA Faculty Development Workshop on Substance Abuse Teaching in Medical School.
26. Swift, R. (1989, October). Substance Abuse and the Orthopedic Patient. National Association of Orthopedic Nurses Annual Meeting, Providence, RI.
27. Swift, R. (1989, October). Dual Diagnosis. Grand Rounds, Butler Hospital, Providence, RI.
28. Swift, R. (1990, January). Workshop Faculty, HHS Faculty Development Workshop on Substance Abuse Teaching in Medical School.
29. Swift, R. (1990, February). Ethanol and Platelet Cyclic AMP. PMA Foundation Annual Meeting, Washington, DC.
30. Swift, R. (1990, March). Substance Abuse. Grand Rounds, St. Luke's Hospital, New Bedford, MA.
31. Swift, R. (1990, March). AIDS and Substance Abuse: A Practical Course for Clinicians. Teaching Faculty, Warwick, RI.
32. Swift, R. (1990, May). Inpatient Treatment of the Pregnant Substance Abuser. Woman and Infants Hospital of RI Forum.
33. Swift, R. (1990, June). Brown University Center for Alcohol and Addiction Studies. Faculty Development Workshop on Substance Abuse Teaching in Medical School, Providence, RI.
34. Swift, R. (1991, February). Ethanol and Platelet Cyclic AMP. Grand Rounds, University of Connecticut Alcohol Center, Farmington, CT.
35. Swift, R. (1991, April). Methods to Quantitate Alcohol Consumption. Invited Presenter, NIAAA Conference, Bethesda, MD.
36. Swift, R. (1992, March). Assessment of Alcohol Consumption with Transdermal Ethanol. McLean Hospital Alcohol and Drug Abuse Center, Belmont, MA.
37. Swift, R. (1992, April). Assessment of Ethanol Consumption with Transdermal Ethanol. University of Chicago Psychiatry Rounds, Chicago, IL.
38. Swift, R. (1992, June). Treatment of Alcohol Dependence and Withdrawal. Westerly Hospital Medical Grand Rounds, Westerly, RI.
39. Swift, R. (1992, October). Treatment of Chronic Pain in Substance Abuse Patients. Grand Rounds, The Medical Center of Central Massachusetts.
40. Swift, R. (1992, October). Psychotropic Drugs and Pregnancy. Grand Rounds, Woman and Infants Hospital, Providence, RI.
41. Swift, R. (1992, November). Nicotine and Cocaine. Symposium Moderator, AMERSA National Conference, Bethesda, MD.
42. Swift, R. Hyperactivity: The Cocaine vs. Ritalin Dilemma. Bradley Hospital Grand Rounds, Discussant, Providence, RI.
43. Swift, R. (1993, January). Naltrexone Effects on Ethanol Intoxication in Non-alcoholic Humans. U. Penn Center for Addiction Research Symposium on Naltrexone.
44. Swift, R. (1993, October). Recent Advances in the Pharmacotherapy of Alcohol Dependence. Loyola University/Hines VA Grand Rounds, Chicago, IL.
45. Swift, R. (1994, January). Use of Withdrawal Scales in the Assessment of Alcohol Withdrawal Symptoms and Pharmacological Modification of Alcohol Intoxication. Visiting Faculty, Yale University/West Haven VA, West Haven, CT.
46. Swift, R. (1994, March). The Biology of Addictions, Brown University CME Course, Course Co-Director and Lecturer, Exeter, RI.
47. Swift, R. (1994, June). Transdermal Ethanol: Principles and Applications. Research Society for Alcoholism Annual Meeting, (Symposium Chair), Maui, HI.

48. Swift, R. (1994, December). Pharmacotherapies for Alcoholism, (Roundtable Discussion Chair), American Academy of Psychiatrists in Alcoholism and Addictions (AAPAA) Annual Meeting,
49. Swift, R. (1995, January). New Treatments for Alcohol Dependence. Medical Grand Rounds, St. Luke's Hospital, New Bedford, MA.
50. Swift, R. (1995, March). Advances in the Pharmacotherapy of Alcoholism. Psychiatry Grand Rounds at the Brockton VA Medical Center, Brockton, MA.
51. Swift, R. (1995, March). New Pharmacotherapies for Alcoholism. Brockton VA/Harvard Department of Psychiatry Grand Rounds, Brockton, MA.
52. Swift, R. (1995, March). Naltrexone in the Treatment of Alcoholism. Central NY ASAM, Buffalo, NY.
53. Swift, R. (1995, April). Pharmacotherapies for Alcoholism. Lecturer at the Central NY Society of Addiction Medicine (ASAM), Albany, NY.
54. Swift, R. (1995, April). Perspectives on Psychopharmacology: New Modalities in the Treatment of Alcohol Dependency. Lecturer at the Annual Meeting of the Maine Psychological Association, Rockland, ME.
55. Swift, R. (1995, April). New Approaches in the Treatment of Alcoholism. Lecturer at the Central New York Academy of Medicine in Utica, NY.
56. Swift, R. (1995, April). The Psychopharmacology of Alcoholism. Psychiatry Grand Rounds at St. Elizabeth Hospital, Brighton, MA.
57. Swift, R. (1995, May). Alcohol and Substance Abuse: Psychopharmacology. Lecturer, Grand Rounds, Brattleboro Retreat, Brattleboro, VT.
58. Swift, R. (1995, June). Health Care Economics for Alcohol Treatment Clinicians. Lecturer, Rush-Presbyterian-St. Luke's Medical Center Symposium, Chicago, IL.
59. Swift, R. (1995, June). Recent Advances in the Treatment of Alcoholism. Invited Lecturer, Drug and Alcohol Association of RI (DATA), Warwick, RI.
60. Swift, R. (1995, June). Advances in Treatments for Alcohol Dependence. Lecturer, Hospital of St. Raphael, New Haven, CT.
61. Swift, R. (1995, July). Assessment and Measurement of Low Dose Alcohol Effects. Participant and Speaker, NIAAA Symposium, Rockville, MD.
62. Swift, R. (1995, August). Pharmacological Treatment of Alcoholism. Psychiatry Grand Rounds, Providence Hospital, Southfield, MI.
63. Swift, R. (1995, December). Health Care Economics for Alcohol Treatment Clinicians. Lecturer, University of Wisconsin Symposium of Advances in Alcoholism Treatment, Madison, WI.
64. Swift, R. (1995, December). Naltrexone in the Treatment of Alcohol Dependence. American Academy of Psychiatrists in Alcohol and Addictions Roundtable Discussion (Chair), Amelia Island, Florida.
65. Swift, R. (1996, January). Psychopharmacology of Alcohol Dependence. Lecturer, Providence VA Mental Health Colloquia Series.
66. Swift, R. (1996, February). Pharmacological Treatment of Opioid and Alcohol Dependence. Lecturer, AMA International Conference on Physician Health, Phoenix, AZ.
67. Swift, R. (1996, February). Pharmacological Treatment of Alcohol Abuse and Dependence. Symposium participant at the 47th Institute on Psychiatric Services, Boston, MA.
68. Swift, R. (1996, April). Pharmacotherapy and Psychotherapy of Alcohol Abuse and Dependence. Medical Grand Rounds, St. Joseph Mercy Hospital, Pontiac, MI.
69. Swift, R. (1996, May). Alcoholism Treatment: From Biology to Economics. Keynote Speaker, Worcester Fights Back Annual Meeting, Worcester, MA.
70. Swift, R. (1996, May). Pharmacological Treatment of Opioid Dependence. Lecturer, Harvard Pilgrim Health Care, Providence, RI.

71. Swift, R. (1996, June). Alcoholism Treatment: From Biology to Economics. Lecturer, State of Tennessee Bureau of Alcohol and Drugs, Nashville, TN.
72. Swift, R. (1997, May). Medical Consequences of Drug Abuse in Adolescents. Lecturer, Lifespan Adolescent Medicine Conference.
73. Swift, R. (1997, May). Pharmacological Treatment of Drug Abuse. Workshop Presenter, American Psychiatric Association Annual Meeting, San Diego, CA.
74. Swift, R. (1997, July). New Developments in Measuring Alcohol Consumption. Symposium Speaker, Research Society for Alcoholism Annual Meeting, San Francisco, CA.
75. Swift, R. (1997, October). Pharmacological Treatment for Smoking Cessation. Lecturer, Correctional Medical Services, Dedham, MA.
76. Swift, R. (1998, March). Pharmacological Treatment for Smoking Cessation. Lecturer, Center for Human Services, New Bedford, MA.
77. Swift, R. (1998, April). Outpatient Detoxification. Workshop Presenter, American Society of Addiction Medicine (ASAM), New Orleans, LA.
78. Swift, R. (1998, September). Measurement of Alcohol Consumption By Transdermal Alcohol. Lecturer at the Pharmacology Department Conference, Tufts University, Boston, MA.
79. Swift, R. (1998, December). Animal and Human Laboratory Models in Alcohol Dependence Research. Symposium Participant, American College of Neuropsychopharmacology Annual Meeting, Los Crobas, PR.
80. Swift, R. (1999, January). NIAAA/U Wisconsin Training Program in Alcoholism Treatment and Research, Part 1, Workshop Faculty, Louisville, KY.
81. Swift, R. (1999, February). Advances in the Pharmacological Treatment of Alcohol and Drug Dependence. Speaker at the Florida Society of Addiction Medicine (FASM), Orlando, FL.
82. Swift, R. (1999, March). New Treatments for Alcohol Dependence. Psychiatry Grand Rounds, St. Luke's Hospital, New Bedford, MA.
83. Swift, R. (1999, June). NIAAA Grantsmanship Workshop at Research Society on Alcoholism Meeting. Speaker and Group Leader, Santa Barbara, FL.
84. Swift, R. (1999, September). NIAAA/U Wisconsin Training Program in Alcoholism Treatment and Research, Part 2, Workshop Faculty, Louisville, KY.
85. Swift, R. (1999, December). Advances in the Pharmacological and Psychosocial Treatment of Alcoholism. Psychiatry Grand Rounds, U. Vermont, Burlington, VT.
86. Swift, R. (2000, February). Substance Abuse Issues. Lecturer, American Academy of Pain Medicine Meeting, New Orleans, LA.
87. Swift, R. (2000, February). Treatment of Anxiety and Depression in Alcohol Dependence. Addiction Grand Rounds, Vanderbilt University.
88. Swift, R. (2000, March). Psychopharmacologic Treatment of Substance Abuse and Dual Diagnosis. Lecturer, RI State Nurses Association, Course in Advanced Psychopharmacology, Providence RI.
89. Swift, R. (2000, April). Advances in the Pharmacological Treatment of Alcoholism. Keynote Speaker, NIAAA/ATTC Symposium for Alcoholism Treatment Providers, Bear Mountain, NY.
90. Swift, R. (2000, May). Identification and Treatment of Addictive Disorders. Speaker for Medical Grand Rounds, Faulkner Hospital, Boston, MA.
91. Swift, R. (2000, May). Neurobiology of Pain and Addiction. Keynote Speaker at Pain and Addiction: Another Dual Diagnosis, Conference at Faulkner Hospital Addiction and Recovery Program, Boston, MA.
92. Swift, R. (2000, June). Medications and Alcohol Craving. Symposium Speaker at the Research Society on Alcoholism Meeting, Denver, CO.

93. Swift, R. (2000, June). RSA/NIAAA Grantsmanship Workshop Group Leader at Research Society on Alcoholism Meeting, Denver, CO.
94. Swift, R. (2000, July). Detoxification from Alcohol and Other Drugs. Speaker, Midwest ATTC Tele-Workshop on Alcoholism.
95. Swift, R. (2000, September). Medications to Treat Alcohol Problems. Roundtable leader and speaker, NIAAA Research to Practice Symposium, Oklahoma City, OK.
96. Swift, R. (2001, January). Medications to Treat Alcohol Dependence. Speaker, Providence VA Medical Center Mental Health Colloquium.
97. Swift, R. (2001, February). Medical Management: Integrating Naltrexone with Behavioral Therapies. Speaker at Research-based Individualized Treatment for Alcoholism Training, Indianapolis, IN.
98. Swift, R. (2001, February). Transdermal Alcohol Measurement for the Estimation of Blood Alcohol Levels. Speaker, NIH Animal Research Facility, Poolesville, MD.
99. Swift, R. (2001, March). The Neuropharmacology of Alcohol Drinking. Speaker, Brown Department of Psychiatry Annual Research Day Symposium.
100. Swift, R. (2001, April). Combining Medications and Behavioral Interventions in Alcoholism Treatment. Course Director and Speaker, American Society of Addiction Medicine (ASAM) Annual Meeting, Los Angeles, CA.
101. Swift, R. (2001, April). Visiting Researcher, Walter B. Jones Alcoholism Treatment Center and Eastern Carolina State University, Greensboro, NC.
102. Swift, R. (2001, May). Alcoholism: Etiology, Treatment and Management. Course Participant, American Gastroenterological Association (AGA) Spring Postgraduate Course, Atlanta, GA.
103. Swift, R. (2001, May). Development of a Transdermal Alcohol Sensor. Participant and Speaker, NIAAA Workshop on Alcohol Sensors, Washington, DC.
104. Swift, R. (2001, June). Low Utilization of Pharmacotherapies in Alcoholism Treatment: Reasons and Solutions. Symposium Chair and Speaker, Research Society on Alcoholism (RSA) Annual Meeting, Montreal, Canada.
105. Swift, R. (2001, June). NIAAA Research Findings—Orientation to Naltrexone and the Integration of Medication into State Treatment Systems. Session Speaker at National Association of State Alcohol and Drug Abuse Directors (NASADAD) Annual Meeting, New Orleans, LA.
106. Swift, R. (2001, July). Naltrexone: Is this a Magic Bullet in Treating Alcohol Addiction? Workshop Faculty at the Summer 2001 Western Michigan University Midwest Institute, Milwaukee, WI.
107. Swift, R. (2001, October). Recent updates on the pharmacotherapy of substance abuse. Keynote Speaker, Grand Rounds, Taunton State Hospital, Taunton MA.
108. Swift, R. (2001, November). Naltrexone and other pharmacotherapies for the treatment of alcoholism. Keynote Speaker, Colorado State Substance Abuse Counselors Annual Meeting, Golden, CO.
109. Swift, R. (2001, December). Alcoholism Treatment Outcome Measures. Participant and Speaker, NIAAA Workshop, Washington, DC.
110. Swift, R. (2002, March). NIAAA Workshop on Pharmacotherapies in Alcoholism, Participant. Bethesda, MD.
111. Swift, R. (2002, March). Grand Rounds speaker on Substance Abuse. St. Luke's Hospital, New Bedford, MA.
112. Swift, R. (2002, April). Naltrexone Treatment of Alcohol Dependence, Faculty Workshop. American Society of Addiction Medicine (ASAM) Meeting, Atlanta, GA.
113. Swift, R. (2002, June). Treating Your Clients' Alcohol Problems: Lessons from the Latest Research. Speaker, NIAAA Workshop, San Francisco, CA.
114. Swift, R. (2002, July). New Options for the Treatment of Alcohol Abuse and Alcoholism. Speaker, CME, Inc., San Diego, CA.

115. Swift, R. (2002, August). Pharmacological Treatments for Alcoholism: An American Perspective. Workshop Participant and Presenter, American Academy of Addiction Psychiatry Roundtable, Saratoga Springs, NY
116. Swift, R. (2002, August). Naltrexone in the Treatment of Alcohol Dependence. Invited Presenter, National Organization of Impaired Driving Programs (NOSIP), St. Louis, MO.
117. Swift, R. (2002, November). Medications to Treat Alcohol Consumption. Evanston Hospital Psychiatry Grand Rounds, Speaker, Evanston, IL.
118. Swift, R. (2002, December). NIAAA Workshop on Combination of Self-reports and Biomarkers. Workshop Speaker and Participant, Bethesda, MD.
119. Swift, R. (2003, January). Pharmacology of Drug and Alcohol Abuse and Dependence. Speaker, National Association of Drug Court Professionals (NADCP) Conference, Washington, DC.
120. Swift, R. (2003, March). NIAAA Workshop on Assessments in Pharmacological Clinical Trials. Workshop Speaker and Participant, Bethesda, MD.
121. Swift, R. (2003, March). Medications to Treatment Alcoholism. Invited Speaker, NHTSA/SAMHSA Conference on Drunk Driving Treatment, Washington, DC.
122. Swift, R. (2003, June). Treating Your Clients' Alcohol Problems: Lessons from the Latest Research. Speaker, NIAAA Workshop, Fort Lauderdale, FL.
123. Swift, R. (2003, June). Medications to treat alcohol dependence: Focus on topiramate. Symposium Co-chair and Speaker. Research Society on Alcoholism Meeting, Fort Lauderdale, FL.
124. Swift, R. (2004, January) Update on Treatment Approaches for Alcohol Dependence, University of Texas Health Sciences Center, San Antonio.
125. Swift, R. (2004, April) Old Wine in New Bottles: Recent Findings on the Neuropharmacology of Alcohol. Brown University Undergraduate Research Day, Providence, RI.
126. Swift, R. (2004, May) Faculty Mentor, Research Colloquium for Junior Investigators, American Psychiatric Association Annual Meeting, New York, NY.
127. Swift, R. (2004, May). Anticonvulsants for the treatment of alcohol dependence. Symposium Co-Chair and Speaker. American Psychiatric Association Annual Meeting, New York, NY.
128. Swift, R. (2004, June). Safety and Efficacy of GABAergic Medications for the Treatment of Alcoholism. Research Society on Alcoholism Annual Meeting, Vancouver, Canada.
129. Swift, R. (2004, June). Choosing Pharmacotherapies for the COMBINE Study. COMBINE Satellite Symposium at Research Society on Alcoholism Annual Meeting, Vancouver, Canada.
130. Swift, R. (2004, Nov). The Etiology of Alcohol Dependence: What Happens in the Brain? Speaker, CME, Inc. Alcohol Abuse and Dependence, Etiology and Treatment. Boston, MA
131. Swift, R. (2005, Feb). The Assessment of Alcohol Consumption by Measurement of Transdermal Alcohol. Alcohol Research Group, Public Health Research Group, Berkeley, CA
132. Swift, R. (2005, March). New Medications for the Treatment of Alcohol Dependence. American Society of Addiction Medicine Regional Meeting, Glastonbury, CT.
133. Swift, R. (2005, March) Tamoxifen (A Protein Kinase C Inhibitor) Compared to Placebo Slightly Alters Alcohol Levels in Men. Eastern Psychological Conference, 76th Meeting of the Eastern Psychological Association Conference, Boston MA.
134. Swift, R. (2005, March). No Change in Mood Measures After Alcohol Administration in Volunteers Taking Tamoxifen. Ninth Annual Research Symposium on Mental Health Sciences, Butler Hospital, Providence, R.I.
135. Swift R. (2005, March). Tamoxifen Slightly Alters Alcohol Levels in Male Volunteers. Ninth Annual Research Symposium on Mental Health Sciences, Butler Hospital, Providence, R.I.
136. Swift, R. (2005, April) Medications to Treat Alcohol Dependence: New Vistas. Arbour-Fuller Hospital Grand Rounds, Attleboro, MA.

137. Swift, R. (2005, April) Medications to Treat Alcohol Dependence: New Vistas. Pembroke Hospital Grand Rounds, Pembroke, MA.
138. Swift, R. (2005, April) Symposium on New Pharmacotherapies for Alcohol Dependence Treatment. American Society of Addiction Medicine Annual Meeting, Dallas, TX.
139. Swift, R. (2005, June) Alcohol Administration to Volunteers Taking Tamoxifen: A Pilot Study. 28th Annual Meeting of the Research Society on Alcoholism. Santa Barbara, CA.
140. Swift, R. (2005, December) Gender Differences in Substance Use by Healthcare Professionals in a State Sample, 44th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii.
141. Swift, R (2006, January). The Impact of Alcohol Dependence on Managed Care Pharmacy. Presentation at Academy of Manage Care Pharmacy Annual Meeting, Seattle, WA.
142. Swift R. (2006, May). Practical Pharmacotherapy of Alcohol Dependence. Workshop Director and Speaker, American Psychiatric Assoc. Annual Meeting, Toronto, CA.
143. Swift R. (2006, May). Pharmacotherapy for the Treatment of Alcohol Dependence: Review of Outcome Data. Speaker in industry sponsored symposium, Sobering Facts: Alcohol Dependence and Treatment Interventions. American Psychiatric Assoc. Annual Meeting, Toronto, CA.
144. Swift R. (2006, June). Faculty for Medication Assisted Addiction Treatment. Clinician Training sponsored by NE Addiction Technology Transfer Center and Mental Health and Substance Abuse Corp of MA, Framingham, MA.
145. Swift R. (2006, June). Symposium Chair, Receptor Polymorphisms and Alcohol Endophenotypes. Research Society on Alcoholism Annual Meeting, Baltimore MD.
146. Swift R. (2006, June). Translating Alcoholism Pharmacotherapy into Clinical Practice. Symposium Discussant, Research Society on Alcoholism Annual Meeting, Baltimore MD.
147. Swift R. (2006, June). Medications to Treat Alcohol Dependence and Treatment of Dual Diagnosis. Visiting Scientist, Walter Reed Army Medical Center, Washington, DC.
148. Swift R. (2006, September). New Medications to Treat Alcohol Dependence. Bridgeport Mental Health Center, Grand Rounds, Bridgeport CT.
149. Swift R. (2006, September). New Medications to Treat Alcohol Dependence, Speaker. University of Rhode Island School of Pharmacy Symposium on Substance Abuse.
150. Swift R, (2006, November). "Pharmacological Treatment of Addictions", Grand Rounds Speaker at St. Lukes Hospital, New Bedford, MA.
151. Swift R. (2007, February). "Medications for the Treatment of Alcohol Dependence", Grand Rounds Speaker at Silver Hills Hospital, New Caanan, CT.
152. Swift, RM. (2007, February). Grand Rounds Speaker. "The Pharmacological Treatment of Alcohol Dependence", Silver Hills Hospital, New Caanan CT.
153. Swift, RM. (2007, April). Grand Rounds Speaker. "Advancing Treatment for Alcohol Dependence". Boston Children's Hospital Adolescent Substance Abuse Program., Boston MA.
154. Swift, RM. (2007, April). Paper Presenter, "Adherence Monitoring in Pharmacotherapy for Alcohol Dependence: A Systematic Review of Naltrexone Clinical Trials", at the American Society of Addiction Medicine (ASAM) Annual Meeting, Miami, FL.
155. Swift R. (2007, May), Panel Member, Pharmacological and Behavioral Treatments for Alcohol Use Disorders: Lessons Learned from the COMBINE Study. MGH Academy Teleconference, Cambridge MA.
156. Swift R (2007 May) Workshop Organizer and Speaker "Practical Pharmacotherapy for the Treatment of Alcohol Dependence" at the American Psychiatric Association Annual Meeting, San Diego CA.
157. Swift R (2007 May) Presenter at "The NIAAA COMBINE Symposium" at the American Psychiatric Association Annual Meeting, San Diego CA.
158. Swift R. (2007, July), Discussant for the symposium, "What's All the Buzz? Laboratory Studies in

Alcohol Intoxication. Research Society on Alcoholism Annual Meeting, Chicago, IL.

159. Swift R. (2007, July), Symposium Co-chair. NIAAA/RSA Grantsmanship workshop. Research Society on Alcoholism Annual Meeting, Chicago, IL.
160. Swift R. (2007, October), "Medications for the Treatment of Alcohol Dependence", Grand Rounds, speaker at University of Hawaii at Manoa, Honolulu, HI
161. Swift R. (2007, December). "Trazodone for Sleep in Alcohol Recovery, presented at the American Academy of Addiction Psychiatry Annual Meeting, San Diego, CA.
162. Swift R. (2007, December). "Adherence Monitoring of Naltrexone: Literature Review of Clinical Trials for Alcohol Dependence", presented at the American Academy of Addiction Psychiatry Annual Meeting, San Diego, CA.
163. Swift R (2008, June) "Five Things You Probably Don't Know About Naltrexone", presented at the University of Pennsylvania Addiction Treatment Research Unit, Philadelphia, PA.
164. Swift R (2009, Oct) "Addiction and Sentencing Recommendations". Presented at the American Bar Association Traffic Court Program, Providence, RI.
165. Swift R (2010, April). "Update on Medications for Alcohol Dependence". Presented at McLean Hospital Course, Addictions in 2010, Boston, MA.
166. Swift R (2010, June) Symposium CoChair. "Extended-release naltrexone for alcohol dependence: from clinical research to clinical practice". Research Society on Alcoholism Annual Meeting, San Antonio, TX.
167. Swift R (2010, April). "Update on Medications for Alcohol Dependence". Presented at McLean Hospital Course, Addictions in 2011, Boston, MA.

INVITED PRESENTATIONS—INTERNATIONAL

1. Swift, R. (1989, March). The relationship between craving and anxiety in opioid withdrawal. Symposium participant at the WFSBP Conference on Non-psychotic Disorders, Jerusalem, Israel.
2. Swift, R. (1996, February). Pharmacological Treatment of Opioid and Alcohol Dependence. Lecturer at the AMA International Conference on Physician Health, Phoenix, AZ.
3. Swift, R. (1996, August). Recent Advances in the Pharmacotherapy of Alcoholism. Symposium Chair and speaker. Tenth World Psychiatry Conference, Madrid, Spain.
4. Swift, R. (1998, June). Reasons for Relapse from Naltrexone for the Treatment of Alcoholism. Symposium speaker at the Canadian College of Neuropsychopharmacology (CCNP), Montreal, Canada.
5. Swift, R. (1998, July). Transdermal Alcohol Measurement of Alcohol Consumption. Poster presentation at the European College of Neuropsychopharmacology, Glasgow, Scotland.
6. Swift, R. (1999, March). Development of a Treatment Improvement Protocol (TIP) for Naltrexone in the Treatment of Alcoholism. Keynote speaker at the Jornados Nacionales Socidrogalcohol, Tenerife, Spain.
7. Swift, R. (1999, May). Treatment Improvement Protocol (TIP) for Naltrexone in the Treatment of Alcoholism. Symposium speaker at the Addiction Conference, Lisbon, Portugal.
8. Swift, R. (2000). Transdermal measurement of alcohol drinking. Poster presentation at the Clinical Pharmacology and Therapeutics Meeting (CPT2000), Florence, Italy.
9. Swift, R. (2004, March). Naltrexone and other pharmacotherapies for the treatment of alcohol dependence. Korean Academy of Addiction Psychiatry, Seoul Korea
10. Swift, R. (2004, March). Psychiatry Grand Rounds: New pharmacotherapies for the treatment of alcohol dependence. Busan University Medical School, Busan Korea.
11. Swift, R. (2004, August). Pharmacotherapies for Alcoholism. Presentation at SAA National Addiction Hospital, Reykjavik, Iceland.

12. Swift, R. (2004, October). Challenges and Opportunities for Medications Development in Alcoholism: An International Perspective in Collaborations between Academia and Industry. Symposium Speaker at the 12th International Society on Biomedical Research on Alcoholism Meeting, Heidelberg/Mannheim, Germany.
13. Swift R. (2006, September). One Year Post-Treatment Follow-up Results for COMBINE. International Society on Biomedical Research on Alcoholism (ISBRA) Meeting, Sydney, Australia.
14. McGeary, JE, Rohsenow, DJ, Tidey, JW, Miranda Jr., R, Swift, RM, Sirota, AD, Monti, PM. (2006, October). A Pharmacogenetic Study of Olanzapine for Urge to Smoke and Nicotine Withdrawal. Poster session presented at the annual meeting of the World Congress of Psychiatric Genetics, Cagliari, Italy.
15. McGeary, C., McGeary, JE, Monti, PM, Rohsenow, DJ, Tidey, J, Miranda Jr., R, MacKillop, J, Swift, RM (2006, October). Alcohol endophenotypes and the val158met polymorphism of the COMT gene. Poster session presented at the annual meeting of the World Congress of Psychiatric Genetics, Cagliari, Italy.
16. Swift R (2008-Feb). Grand Rounds/CME Speaker, The Management of Patients with Co-Occurring Pain and Addiction. LBJ Hospital for Tropical Diseases, Pago Pago, American Samoa.
17. Swift R and Ray LA (2008-May) Stress Opioid Systems and Naltrexone Response at the Symposium, "Alcohol and Stress: A Framework for Future Treatment Strategies", Volterra, Italy.
18. Swift R (2009-Feb). Grand Rounds/CME Speaker. Identification and treatment of Alcohol Problems. LBJ Hospital for Tropical Diseases, Pago Pago, American Samoa.
19. Swift R (2009-Jun). Studying Laboratory Alcohol Consumption, Workshop Co-Chair and Speaker. European Society for Biomedical Research on Alcoholism (ESBRA). Helsinki, Finland.
20. Swift R (2009-Nov). Challenges in Designing Alcoholism Clinical Trials and Analyzing Outcomes: Abstinence versus Harm Reduction. Presented at the Asian Pacific Society for Alcohol and Addiction (APSAAR), Seoul, Korea.
21. Swift RM (2010-Aug). Visiting Professor and Seminar Presenter: Advances in the Treatment of Alcoholism. Chris Hani Baragwanath Hospital, Soweto, South Africa
22. Swift RM (2010-Sep). Ethanol's Stimulant Effects and Sensitization in Humans: Clinical Relevance. Presented at the Symposium: Ethanol Sensitization: Thirty Years of Research into Its Mechanisms and Contributions to Alcohol Use Disorders, International Society for Biomedical Research on Alcoholism (ISBRA) Meeting, Paris, France.
23. Swift RM (2011-Sep). Effects of Ondansetron, sertraline and the 5HTTLPR polymorphisms on naturalistic and laboratory alcohol consumption in non-treatment seeking alcohol dependent subjects. European Society for Biomedical Research on Alcoholism (ESBRA) Meeting, Vienna, Austria.

ACTIVE GRANTS AND CONTRACTS

- 1) R01 AA015753-01 (Swift – PI) 9/15/07 - 5/31/12 2.4 cal mo
NIAAA \$356,138
Aripiprazole and Topiramate for Free-Choice Alcohol Use
The primary aims of this research are to: (1) determine if the combination of aripiprazole (APZ) and topiramate (TPMT) is more effective than either drug alone in reducing alcohol use in non-treatment seeking alcohol-dependent subjects in an alcohol self-administration experiment; (2) examine the relations between APZ, TPMT alone and together on craving; and (3) establish the adverse reactions of administering APZ and TPMT together with alcohol.
- 2) CSP#563 (Swift- PI) 01/01/09 – 12/31/12 1.5 cal mo
VA \$450,000
Prazosin and Combat Trauma PTSD (PACT)
This multi-site study is a placebo controlled clinical trial investigating the effect of the alpha antagonist prazosin on nightmares and PTSD symptoms.
Role: Site Principal Investigator
- 3) R03AA020169 (Leggio-PI) 9/25/10- 8/31/12 0.9 cal mo
NIAAA \$275,000
Effects of Baclofen on Alcohol Cue-Elicited Urges to Drink and Smoke
The present study has the goal to add a laboratory biobehavioral component to the parent ABMRF-funded study. Specifically, this R03 SOAR sub-study project will be a 1-day double-blind, placebo-controlled, between-subject randomized cue-reactivity (CR) experiment with baclofen conducted in those alcohol-dependent nicotine-dependent participants of the parent study.
- 4) R21 AA019709 (Leggio-PI) 9/10/10- 8/31/12 0.24 cal mo
NIAAA \$275,000
Effects of Ghrelin on Alcohol Cue Reactivity and Craving
This study has the goals to: i) conduct an alcohol laboratory study testing the role of ghrelin i.v., therefore demonstrating the feasibility of such a study and the safety of ghrelin i.v. when administered to alcohol-dependent individuals; and ii) explore the effects of ghrelin i.v. on alcohol craving assessed under controlled conditions, such as a cue-reactivity experiment.
- 5) 1 R01 DA026778-01 (Miranda-PI) 6/15/09 – 5/31/11 .2 cal. mo.
NIDA \$343,757
Biobehavioral effects of topiramate on cannabis-related outcomes in adolescents.
This study will help to determine whether the medication, topiramate, reduces cannabis use among adolescents with cannabis abuse or dependence.
Role: Co-investigator
- 6) R21 AA017273-01A1 (Miranda-PI) 9/1/08 – 8/31/11 .2 cal. mo.
NIAAA \$275,000 No cost extension
Mechanisms of Naltrexone Action on Drinking in Adolescents
The major purpose of the proposed exploratory study (R21) is to provide important new information about the mechanisms of NTX action in adolescents while establishing the utility of a comprehensive yet efficient paradigm for studying mechanisms of pharmacotherapy action in youth.
Role: Co-investigator
- 7) R01 DA024652-01 (Rohsenow - PI) 6/15/08 - 3/31/13 .48 cal. mo.
NIDA \$441,794
Varenicline and motivational advice for smokers with SUD
The study investigates the effects of varenicline and transdermal nicotine as adjuncts to motivational counseling for smoking cessation for smokers in residential treatment for substance dependence.
Role: Co-investigator

- 8) R01 AA016079 (Kenna-PI) 9/30/07 - 8/31/11 (no cost ext.) 1.2 cal mo
 NIAAA \$249,547
 Matching 5-HT Genotypes To Serotonergic Medications For Alcoholism
 The primary aim of this study is to evaluate the efficacy of ondansetron for reducing drinking in participants who carry the LL variant of the serotonin transporter gene (5-HTTLPR); evaluate the efficacy of sertraline for reducing drinking in participants who carry either the SL or SS variants of the 5-HTTLPR in an alcohol self-administration experiment.
- 9) R01AA07850-16 (Monti PI) 1/1/06 - 12/31/10 (no cost ext.) .6 cal mo.
 NIAAA \$328,134
 Biobehavioral Mechanisms of Topiramate and Drinking
 This project will provide an efficient and comprehensive analysis of the effects of topiramate on drinking and craving and add important new information about putative biobehavioral mechanisms of topiramate's effects.
 Role: Co-investigator
- 10) R01-DA 020725-01A2 (White - PI) 8/15/07 – 5/31/11 .6 cal. mo.
 NIDA \$232,710
 Imaging Individual Differences in Amphetamine Effects
 Project investigates individual differences in fMRI brain response to d-amphetamine in healthy young adults.
 Role: Co-investigator
- 11) R21AA017696 (MacKillop) 4/1/10 - 3/31/12 .6 cal. mo.
 NIAAA \$444,032
 D-Cycloserine to Enhance Extinction to Alcohol Cues
 This is an exploratory laboratory study to determine d-cycloserine enhances extinction learning in treatment-seeking alcoholics.
- 12) R21 AA019994 (PI: Leggio) 9/1/11-8/31/13 .6 cal mo.
 NIAAA \$425,250
 Doxazosin an alpha-1 Antagonist for Alcohol Dependence
 The primary aim of this study is to randomize treatment-seeking alcohol dependent individuals to test the effects of the alpha-blocker doxazosin in reducing alcohol craving and drinking.

GRANTS AND CONTRACTS PENDING

R01 AA007850-21 (PI: R. Miranda, Jr.) Pending (10th percentile) 1.2 cal mo
 NIAAA \$2,102,535
 Effects of Topiramate on Adolescent Alcohol Use: Efficacy and Mechanisms

COMPLETED GRANTS AND CONTRACTS

<u>No.</u>	<u>Years</u>	<u>Source of Funding</u>	<u>Grant Title</u>	<u>Role</u>	<u>Amount</u>
1.	1985-1988	Pharmaceutical Mfg. Association Foundation	Clinical Pharmacology Unit Grant	PI	\$50,000
2.	1986-1988	Alcohol Beverage Med. Res. Fdn. (ABMRF)	Effects of Ethanol on Leukocyte Cyclic AMP Formation	PI	\$30,000
3.	1986	Brown University Maxtrix Grant	Pharmacokinetic Interactions between Methadone and Alcohol in Human Volunteers	PI	\$7,500

4.	1986	Rhode Island Foundation	Effects of Ethanol on Leukocyte Cyclic AMP Formation	PI	\$3,000
5.	1987-1990	NIAAA	Studies on Alcohol and the Leukocyte Beta Adrenergic Receptor, New Investigator Award	PI	\$117,500
6.	1987-1992	NIAAA/NIDA	Treatment Prevention Research Training Grant, Director of Biological Sciences	Lewis, PI Co-I	10% effort
7.	1987-1992	NIAAA Contract	Working Committee, Integrated Model Program & Curriculum Alcohol & Drug Abuse for Primary Care Physician Education	Lewis, PI Co-I	10% effort
8.	1989-1992	ADAMHA-SBIR Phase II Dev. Grant	Giner Transdermal Alcohol Sensor – Clinical Study	Giner, PI Co-I	\$82,000
9.	1990-1991	Bristol Myers	Neuropsychiatric Aspects of D4T in AIDS	Whelihan- PI Co-I	\$50,000
10.	1990-1993	NIAAA/NIDA 1-T01-AA07514	Clinical Training Grant for Faculty Development in Alcohol & Other Drug Abuse (Awarded for Faculty Fellow)	PI	\$45,000
11.	1991-1994	CSAP	Project Link	Sweeney, PI Co-I	\$10,320
12.	1992-1993	Brown University Ctr. For Alcohol & Addiction Studies	(Research Improvement Award) Effect of Naltrexone on Alcohol Intoxication	PI	\$6,200
13.	1993-1994	Burroughs Welcome	Safety Surveillance Study for Sustained Release of Wellbutrin	PI	\$15,000
14.	1993-1994	Brown University Dept. of Psychiatry, Pilot Grant	Effect of Ondansetron on Ethanol Intoxication.	PI	\$10,000
15.	1994	Dupont Merck	Safety & Effectiveness of Naltrexone Administered with Psychosocial Therapy in the Treatment of Alcoholism	PI	\$75,000
16.	1994-1997	NIAAA R01 AA09249	Assessment of Alcohol Consumption by Transdermal Ethanol	PI	\$709,000
17.	1994-1999	NIAAA	Coping, Cue & Naltrexone Treatment	Monti, PI Co-I	\$1,200,000
18.	1995-1996	NIAAA Contract	Pharmacokinetic & Behavioral Effects of Intravenous Low-dose Alcohol	PI	\$10,350
19.	1996-1998	Pfizer, Inc.	Tryptophan Depletion in Depressed Alcoholics	PI	\$69,000

20.	1996-1998	Pfizer, Inc.	Multi- Site Double-blind Parallel Comparison of Sertraline & Placebo in Outpatients with Concurrent DSM-IV, Major Depression & Alcohol Dependence	Site PI	\$236,000
21.	1996-1998	Alcohol Beverage Medical Research Foundation (ABMRF)	Effects of Naltrexone on Alcohol Drinking by Non-Alcoholic Drinkers in a Cocktail Bar Setting	Davidson, PI Co-I	\$33,484
22.	1996 – 1998	Pharmacia Upjohn	Study of CDTest E1S, An Enzyme Immunoassay for Quantitative Measurement of Carbohydrate Deficient Transferring for Monitoring Abstinence & Relapse in Patients Treated for Alcohol Dependence	Site PI	\$130,000
23.	1996-2001	NIAAA – R01 AA11211	Motivating Alcoholics to Quit Smoking	Abrams, PI Co-I	\$2,289,980
24.	1997-1999	NIAAA – R01 AA11796	Alcohol Education in Needle Exchange Participants	Stein, PI Co-I	10% effort
25.	1997-2000	NHLBI/NIH R01 HL32318	Matching Antidepressant Treatment for Smoking Cessation	Niaura, PI Co-I	5% effort
26.	1997 – 2006	NIAAA/NIH U10AA11777	Project COMBINE: Combined Pharmacological & Behavioral Treatment of Alcoholism: Clinical Research Unit	PI (as of 2000)	\$1,400,000
27.	1998-2002	NIAAA R01 AA10945	Diffusion of Naltrexone into Alcohol Treatment	Wallack, PI Co-I	\$1,200,000
28.	1989-2001	Contral Pharma	CPH-101 in Heavy Alcohol Drinkers with Impaired Control: A 12+40 Week Placebo Controlled Dose Response Study	PI	\$146,000
29.	1999-2002	NIAAA/NIH N43 AA82005	Miniaturized Transdermal Alcohol Sensor (SBIR Phases 1 & 2)	Swette, PI Co-I	\$100,000
30.	2000-2001	Drug Abuse Sciences	Naltrel in Alcohol Dependent Heavy Drinkers	PI	\$95,000
31.	2000-2006	NIAAA/NIH	Naltrexone, Craving & Drinking: Ecological Assessment	Monti, PI Co-I	10% effort
32.	2000-2005	NIAAA/NIH	Naltrexone & Broad Spectrum Psychotherapy	Davidson, PI Co-I	10% effort
33.	2001-2007	NIDA R01 DA15327	Drug Reduction Intervention for Needle Exchange Clients	Gogineni, PI Co-I PI as of 2005	5% effort Inc.to 10%
34.	2001-2006	NIAAA 5T32 AA07459-15	Alcohol Intervention/Treatment Outcome Research Training Grant	Monti, PI Co-I , (Ass.Dir)	

35.	2001-2006	NIDA R01 DA14002	Transdermal Nicotine & Bupropion SR in Schizophrenics	Tidey, PI Co-I	10% effort
36.	2002-2006	NIAAA/NIH N01 AA3302	An Integrated Transdermal Alcohol Sensor & Data Analysis System (A Subcontract with Giner, Inc.)	PI	\$3,100,000
37.	2003-2004	Pfizer	Randomized, Placebo-Controlled Parallel Group Study Comparing Effect of Three Doses of CP866,087 & Naltrexone on Acute Alcohol Consumption & Craving After 7 Days of Treatment in Alcohol Dependent (DSM IV) Subjects Not Currently Seeking Treatment	PI	
38.	2003-2005	Ortho-McNeil	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study to Assess the Safety & Efficacy of Topiramate in the Treatment of Alcohol Dependence	Site PI	
39.	2003-2008	NIAAA R01 AA013880	Ondansetron & Naltrexone: Cue Reactivity & Drinking	Rohsenow, PI Co-I	10% effort
40.	2005-2008	NIAAA/SBIR R44AA14118	Wireless, Low Maintenance Transdermal Alcohol Sensor, Phase 2 (subcontract with Giner, Inc.)	Tempelman, PI Sub PI	5% effort
41.	2006-2007	VA CSP #1024	A Phase III Randomized Multi-Center Double-Blind, Placebo-Controlled Study of the Safety & Efficacy of Lofexidine for the Relief of Symptoms in Subjects Undergoing Inpatient Opiate Detoxification	Site PI	
42.	2006-2010	NIAAA 2R01 AA07850-16	Biobehavioral Mechanisms of Topiramate and Drinking	Monti, PI Co-I	\$2,865,476
43.	2006-2008	NIAAA CSP 1027 Medications Development Contract	Multi-Center Double-blind, Placebo-Controlled Study of Quetiapine for the Treatment of Alcohol Dependence	Site PI	\$591,000
44.	2007-20010	NIAAA R21 AA016597	Alcohol Phenotype Development in American Samoa	PI	\$255,000 5% effort
45.	2008-2010	NIAAA	Contingency Management for Alcohol Abuse Using Transdermal Alcohol Detection	Barnett, PI Co-I	\$262,500
46.	2009-2010	Eli Lilly	NABJ – LYxxxxx in Alcohol Dependence	Site PI	\$250,000

UNIVERSITY TEACHING ROLES

1983 – 1990	Lecturer, BioMed 363, Integrated Medical Sciences (Pharmacology), Brown Medical School
1985 – 1997	Faculty Attending for Brown Psychiatry Residents on Consultation-Liaison Psychiatry Service at Roger Williams Medical Center
1986 – 1988	Small Group Leader, BioMed 390, Medical Interviewing, Brown Medical School
1986 – 1990	Co-Leader and Lecturer, Major Clinical Syndromes Seminars, Brown Medical School, Department of Psychiatry
1987 – present	Training Faculty, Seminar Leader and Lecturer, NIAAA T32 Alcohol Prevention/Treatment Training Grant
1990 – present	Lecturer, PGY3, PGY4 Psychiatry Residents Seminars
1994 – 2002	Lecturer, Advanced Pathophysiology, University of Rhode Island School of Pharmacy
1997 - -present	Associate Director, NIAAA T32 Alcohol Prevention/Treatment Postdoctoral Training Grant
1997 – present	Supervisor and Attending for Brown Psychiatry Residents on Outpatient Rotation at the VA Medical Center
1998 – present	Preceptor, Bio 195 and Bio 196 (Independent Study), Brown University
1999 – present	Faculty Mentor, Brown University Faculty Mentorship Program
2001, 2004	Faculty Advisor and Main Reader for Undergraduate Honors Thesis, Brown University (Benjamin Mega, Elizabeth Fernandez)
2003 – 2006	Preceptor, Community Health Clerkship
2005 – present	Lecturer, Treatment of Substance Abuse BioMed 370

HOSPITAL TEACHING ROLES

1984-1995	Clinical Supervisor, C-L Service, Roger Williams Hospital
1996-present	Outpatient Supervisor for Psychiatry Residents at the Providence VA Medical Center

MENTORING

<u>Post-doctoral</u>	<u>Dates</u>	<u>Current Position</u>
Paolo DePetrillo, M.D.	1987-1990	Senior Investigator, NIH/NIAAA Intramural Prgrm.
Timothy Mueller, M.D.	1990-1991	Professor of Clinical Psychiatry, U. Arizona (S. Arizona VAMC)
Christopher Martin, Ph.D	1992-1993	Assoc. Professor of Psychiatry, U of Pittsburgh
Oleg Kuznetsov, M.D.	1993-1995	Radiology (non-academic)
*Josiah Rich, M.D.	1995-1999	Professor of Medicine (Community Health) Brown U.
*Dena Davidson, Ph.D.	1996-1999	Assoc. Prof. Psychiatry, U. Indiana Medical School
*Kent Hutchison, Ph.D.	1997-2000	Prof. Psychology/Neuroscience, U. New Mexico
Tibor Palfi, Ph.D.	1997-1999	Professor of Psychology, Syracuse University
Walter Adams, Ph.D.	1998-1999	Adjunct Faculty, Brown University
*Denise Bury-Maynard, Ph.D.	2000-2001	Scientist, Pfizer, Inc.

Cindy Parks-Thomas, Ph.D.	2000-2003	Senior Scientist, Brandeis University
Irene Glasser, Ph.D.	2000-2003	Sr. Planning/Research Analyst, Community Renewal Team, Hartford CT
Ali Eslami, M.D.	2001-2004	Psychiatry Resident, U Calif San Diego
*John McGeary, Ph.D.	2002-2005	Asst. Prof. Psychiatry, Brown University
George Kenna, Ph.D., R.Ph.	2003-	Asst. Prof. Psychiatry, Brown University
Lorenzo Leggio, M.D.	2008-	Asst. Prof. Comm Health, Brown University
Tara White, Ph.D.	2003-2005	Asst. Prof. Psychiatry, Brown University
John Hayes, Ph.D.	2006-2009	Asst. Prof. Food Science, Penn State
Lara Ray, Ph.D.	2007-2009	Asst. Prof. Psychiatry, UCLA
Christy Capone, Ph.D.	2007-2009	Asst. Prof. Psychiatry, Brown University

Junior Faculty	Dates	Current Position
Mark Aloia, Ph.D.	1998-2002	Asst. Prof. Psychiatry, Brown U.,
*Maria Pagano, Ph.D.	2001-2002	Asst. Prof. Psychiatry, Brown U.
John Holter, M.D.	2001-2002	Asst. Clin Professor, E. Carolina State Univ.
Mark Eliasson, Ph.D.	2002-03	Asst. Professor Psychiatry, U. Kentucky
*Robert Miranda, Ph.D.	2002-	Asst. Prof. Psychiatry, Brown University
*Thomas Chun, M.D.	2005-	Asst. Prof. Psychiatry, Brown University
Tahir Tellioglu, M.D.	2006-	Asst. Prof. Psychiatry, Brown University

*Mentor for Funded NIH Career Development (K) Award or VA Career Development Award